Page last updated: 2024-12-04

amsacrine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Amsacrine: An aminoacridine derivative that intercalates into DNA and is used as an antineoplastic agent. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

amsacrine : A sulfonamide that is N-phenylmethanesulfonamide substituted by a methoxy group at position 3 and an acridin-9-ylamino group at position 4. It exhibits antineoplastic activity. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID2179
CHEMBL ID43
CHEBI ID2687
SCHEMBL ID4047
MeSH IDM0001039

Synonyms (111)

Synonym
nsc-249992
wln: t c666 bnj imr bo1 dmsw1
amsine
methanesulfonamide, n-[4-(9-acridinylamino)-3-methoxyphenyl]-
NCIMECH_000607
NCI60_001995
amecrin
4'-(9-acridinylamino)methanesulfon-m-anisidide
n-[4-(acridin-9-ylamino)-3-methoxyphenyl]methanesulfonamide
amsacrinum
4'-(9-acridinylamino)methanesulphon-m-anisidide
4'-(9-acridinylamino)methanesulfon-meta-anisidide
CHEBI:2687 ,
sn-11841
ci-880
amsacrina
n-[4-(acridin-9-ylamino)-3-(methyloxy)phenyl]methanesulfonamide
amsa, m-
n-(4-(9-acridinylamino)-3-methoxyphenyl)methanesulfonamide
amsa
lopac-a-9809
NCGC00015113-01
NEURO_000118
LOPAC0_000154
lamasine
m-amsa
NSC249992 ,
namsa
amsidine
amsidyl
n-[4-(9-acridinylamino)-3-methoxy-phenyl]methanesulfonamide
amekrin
sn 21429
methanesulfonanilide, 4'-(9-acridinylamino)-3'-methoxy-
amsacrinum [inn-latin]
nsc 156303
nsc 249992
meta-amsacrine
methanesulfonamide, n-(4-(9-acridinylamino)-3-methoxyphenyl)-
c21h19n3o3s
einecs 257-094-3
ci 880
brn 0500176
hsdb 7087
amsacrina [inn-spanish]
methanesulfon-m-anisidide, 4'-(9-acridinylamino)-
acridinylanisidide
ccris 1027
mamsa
C01553
amsacrine
51264-14-3
4'-(9-acridinylamino)-3'-methoxymethanesulfonanilide
nsc-156303
acridinyl anisidide
DB00276
D02321
amsidyl (tn)
amsacrine (usan/inn)
NCGC00162077-01
n-(4-(acridin-9-ylamino)-3-methoxyphenyl)methanesulfonamide
NCGC00015113-03
CHEMBL43 ,
nci-249992
amsidil
sn-21429
n-[4-(9-acridinylamino)-3-methoxyphenyl]methanesulfonamide
AKOS015917522
CCG-35555
NCGC00015113-02
NCGC00015113-04
ASW ,
amsacrine [usan:inn:ban]
00dpd30soy ,
5-22-11-00030 (beilstein handbook reference)
unii-00dpd30soy
amsacrine [usan]
amsacrine [iarc]
amsacrine [mi]
amsacrine [vandf]
amsacrine [hsdb]
amsacrine [mart.]
amsacrine [inn]
amsacrine [who-dd]
CS-1942
HY-13551
MLS006010099
smr000857391
SCHEMBL4047
n-[4-(acridin-9-ylamino)-3-methoxy-phenyl]methanesulfonamide;hydrochloride
cid_148673
n-[4-(9-acridinylamino)-3-methoxyphenyl]methanesulfonamide;hydrochloride
bdbm87351
4'-(9-acridinylamino)-methylsulfonyl-m-anisidine
4'-(9-acridinylamino)methanesulfonyl m-anisidide
DTXSID4022604
n-{4-[(acridin-9-yl)amino]-3-methoxyphenyl}methanesulfonamide
Q2784004
FT-0708980
AS-11665
BCP08958
SDCCGSBI-0050142.P003
NCGC00093644-10
HMS3748E05
m-amsa hydrochloride; acridinyl anisidide hydrochloride
m-amsa;acridinyl anisidide
C75400
A918341
mfcd00242748
BCA26414
EN300-7481264

Research Excerpts

Overview

Amsacrine (m-AMSA) is an anticancer agent that displays activity against refractory acute leukemias as well as Hodgkin's and non-Hodgkin's lymphomas. Amsacine is a DNA intercalating agent with antineoplastic properties in lymphoproliferative disorders.

ExcerptReferenceRelevance
"Amsacrine is an anilinoacridine derivative anticancer drug, used to treat a wide variety of malignancies. "( Role of minor groove width and hydration pattern on amsacrine interaction with DNA.
Jangir, DK; Kundu, S; Mehrotra, R, 2013
)
2.08
"Amsacrine analog is a novel chemotherapeutic agent that provides potentially broad antitumor activity when compared to traditional amsacrine. "( Amsacrine analog-loaded solid lipid nanoparticle to resolve insolubility for injection delivery: characterization and pharmacokinetics.
Chen, YL; Chuang, CH; Fang, YP; Huang, YB; Liu, YT; Tsai, MJ; Tsai, YH; Tzeng, CC; Wu, PC, 2016
)
3.32
"Amsacrine is an effective topoisomerase II enzyme inhibitor in acute lymphatic leukemia. "( Computational analysis of Amsacrine resistance in human topoisomerase II alpha mutants (R487K and E571K) using homology modeling, docking and all-atom molecular dynamics simulation in explicit solvent.
Sader, S; Wu, C, 2017
)
2.2
"Amsacrine (m-AMSA) is an anticancer agent that displays activity against refractory acute leukemias as well as Hodgkin's and non-Hodgkin's lymphomas. "( Amsacrine as a topoisomerase II poison: importance of drug-DNA interactions.
Denny, WA; Graves, DE; Ketron, AC; Osheroff, N, 2012
)
3.26
"Amsacrine is a rationally designed anticancer drug, used to treat leukemia and lymphoma."( Assessment of amsacrine binding with DNA using UV-visible, circular dichroism and Raman spectroscopic techniques.
Dey, SK; Jangir, DK; Kundu, S; Mehrotra, R, 2012
)
1.46
"Amsacrine is an acridine derivative drug applied in haematological malignancies. "( Free radical scavengers can differentially modulate the genotoxicity of amsacrine in normal and cancer cells.
Blasiak, J; Drzewoski, J; Gloc, E; Pertynski, T; Skórski, T; Wozniak, K; Zadrozny, M, 2003
)
1.99
"Amsacrine is a 9-anilinoacridine derivative that appears to act as an electron donor in ET reactions on DNA, while N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA) may act as an electron acceptor."( Mechanisms of action of DNA intercalating acridine-based drugs: how important are contributions from electron transfer and oxidative stress?
Baguley, BC; Jacintho, JD; Kovacic, P; Wakelin, LP, 2003
)
1.04
"Amsacrine is a DNA intercalating agent with antineoplastic properties in lymphoproliferative disorders. "( Bacterial and mammalian cell mutagenesis, sister-chromatid exchange, and mouse lung adenoma bioassay with the antineoplastic acridine derivative amsacrine.
de la Iglesia, FA; Fitzgerald, JE; Heifetz, CL; Kim, SN; McGuire, EJ; Stoner, GD, 1984
)
1.91
"Amsacrine is an effective replacement for daunorubicin in the treatment of APL, and its use does not compromise the favorable remission duration characteristic of APL."( Primary therapy of acute promyelocytic leukemia: results of amsacrine- and daunorubicin-based therapy.
Arlin, Z; Chaganti, RS; Clarkson, B; Gee, T; Higgins, C; Jhanwar, S; Kempin, S; Mertelsmann, R, 1984
)
1.23
"Amsacrine is an aminoacridine that binds to DNA by intercalation. "( Induction of small intestinal adenocarcinomas in Wistar rats administered amsacrine.
Courtney, C; Gough, A; Graziano, M, 1994
)
1.96
"Amsacrine is an antineoplastic drug used in the treatment of acute adult leukemias. "( Carcinogenicity of the anticancer topoisomerase inhibitor, amsacrine, in Wistar rats.
Courtney, CL; Gough, AW; Graziano, MJ; Kheoh, T; Meierhenry, EF; Pegg, DG, 1996
)
1.98
"Amsacrine is an intercalating planar polycyclic aromatic molecule that displays antitumor activity. "( [Cytotoxicity and interaction of amsacrine derivatives with topoisomerase II: role of the 1' substitute on the aniline nucleus].
Bailly, C; Fossé, P; Jacquemin-Sablon, A; Khélifa, T; René, B, 1997
)
2.02
"Amsacrine is an acridine-derived inhibitor of topoisomerase II that intercalates into DNA. "( Amsacrine-induced mutations in AS52 cells.
Ferguson, LR; Hart, DW; Tindall, KR; Turner, PM, 1998
)
3.19
"Amsacrine is a DNA intercalating agent which is active against a number of tumours in mice and is used for the treatment of leukaemia in humans. "( The possible role of electron-transfer complexes in the antitumour action of amsacrine analogues.
Baguley, BC, 1990
)
1.95
"Amsacrine is an active antileukemic agent known to induce cardiac arrhythmias, although the incidence of these cardiac events is low. "( Amsacrine is safe in patients with ventricular ectopy.
Arlin, ZA; Feldman, EJ; Puccio, CA, 1988
)
3.16
"Amsacrine is an antileukemia drug being widely used in North America, Europe, Australia, and New Zealand. "( Amsacrine-associated cardiotoxicity: an analysis of 82 cases.
Grillo-López, AJ; Hess, F; Marsoni, S; Posada, JG; Ross, BJ; Weiss, RB, 1986
)
3.16
"Amsacrine is an acridine derivative that has been extensively evaluated for its antitumor activity in recent years. "( Amsacrine: a review.
Cassileth, PA; Gale, RP, 1986
)
3.16
"Amsacrine (NSC 249 992) is a new anticancer drug which, although effective for the treatment of various disseminated tumors, has shown disappointing activity against most solid tumors. "( Comparison of the pharmacokinetics and protein binding of the anticancer drug, amsacrine and a new analogue, N-5-dimethyl-9-[(2-methoxy-4-methylsulfonylamino)phenyl-amino] -4-acridinecarboxamide in rabbits.
Jurlina, JL; Paxton, JW, 1986
)
1.94

Effects

Amsacrine (AMSA) has been shown to be an effective therapeutic agent in the treatment of adult acute nonlymphocytic leukemia (ANLL) But amsacrine has been forgotten in clinical studies of transitional cell carcinoma of the urinary bladder.

ExcerptReferenceRelevance
"Amsacrine (AMSA) has been shown to be an effective therapeutic agent in the treatment of adult acute nonlymphocytic leukemia (ANLL). "( High-dose amsacrine (AMSA) therapy of relapsed and refractory adult acute nonlymphocytic leukemia. A phase II study.
Bennett, JM; Cassileth, PA; Glick, JH; Lyman, GH; Oken, MM, 1984
)
2.11
"But amsacrine has been forgotten in clinical studies of transitional cell carcinoma of the urinary bladder."( Amsacrine and cisplatin in poor prognosis patients with metastatic transitional cell carcinoma of the urothelium: a phase-II study.
Jelíc, S; Nikolíc-Tomasevíc, Z; Popov, I; Radosavljevíc, D, 2001
)
2.23

Treatment

ExcerptReferenceRelevance
"Amsacrine treatment triggered SIDT2-mediated miR-25 downregulation, leading to increased NOX4-mediated ROS production."( Amsacrine downregulates BCL2L1 expression and triggers apoptosis in human chronic myeloid leukemia cells through the SIDT2/NOX4/ERK/HuR pathway.
Chang, LS; Chen, YJ; Chiou, JT; Lee, YC; Wang, LJ, 2023
)
3.07

Toxicity

Both compounds are more cytotoxic than etoposide but much less toxic than amsacrine toward L1210 leukemia cells. Amsacrine is safe and effective therapy for patients with acute leukemia and cardiac disease.

ExcerptReferenceRelevance
" Amsacrine is safe and effective therapy for patients with acute leukemia and cardiac disease."( Amsacrine is safe and effective therapy for patients with myocardial dysfunction and acute leukemia.
Ahmed, T; Arlin, ZA; Baskind, P; Chun, HG; Cook, P; Feldman, EJ; Marboe, C; Mehta, R; Mittelman, A; Puccio, C, 1991
)
2.63
" Quantifying the embryotoxic effects of these drugs revealed that the no observed adverse effect level (NOAEL) for m-AMSA is 10 nM, the embryotoxic concentration range is 50-500 nM, and complete lethality is observed at 1 microM."( Embryotoxicity of the intercalating agents m-AMSA and o-AMSA and the epipodophyllotoxin VP-16 in postimplantation rat embryos in vitro.
Mirkes, PE; Zwelling, LA, 1990
)
0.28
" These two DNA intercalators differed significantly in their cytotoxic potential, mitoxantrone being 24-fold more toxic than mAMSA when assayed by the inhibition of clonogenicity."( Long-term inhibition of DNA synthesis and the persistence of trapped topoisomerase II complexes in determining the toxicity of the antitumor DNA intercalators mAMSA and mitoxantrone.
Fox, ME; Smith, PJ, 1990
)
0.28
" The LD50 values observed in normal and leukemic Brown-Norway rats were 26."( AMSA: in vivo log cell kill for leukemic clonogenic cells versus toxicity for normal hemopoietic stem cells in a rat model for human acute myelocytic leukemia (BNML).
Hagenbeek, A; Martens, AC, 1986
)
0.27
" These data, together with reports indicating a protective effect of ruthenium red against vinblastine and anthracycline toxicity, suggest that the dye promotes tight binding of m-AMSA and other agents to cellular loci on which toxic effects are not exerted."( Effects of ruthenium red on accumulation and cytotoxicity of m-AMSA, vinblastine and daunorubicin in leukemia cells.
Kessel, D; Wilberding, C, 1984
)
0.27
"The antitumor activity and toxic effect of AMSA were studied in Lewis lung carcinoma (3LL) at various stages of growth."( Influence of scheduling on therapeutic and toxic effect of AMSA in Lewis lung carcinoma.
Badaracco, G; Greco, C; Zupi, G, 1983
)
0.27
" The toxic effect was also lower for liposome preparations."( [Examination of the toxicity of the liposomal form of amsacrine and retinoic acid].
Tarasiuk, A, 1992
)
0.53
" Doxorubicin and 4-epi-doxorubicin showed the greatest cytotoxic effect after 3 h and were also more toxic to normal bone marrow cells from donors over 40 years of age."( Toxicity of cytostatic drugs to normal bone marrow cells in vitro.
Paul, C; Sundman-Engberg, B; Tidefelt, U, 1998
)
0.3
" Both hybrid compounds are more cytotoxic than etoposide but much less toxic than amsacrine toward L1210 leukemia cells."( Design of two etoposide-amsacrine conjugates: topoisomerase II and tubuline polymerization inhibition and relation to cytotoxicity.
Arimondo, P; Bailly, C; Boukarim, C; Dauzonne, D; Monneret, C, 2000
)
0.84
"This trial determined that it is safe and feasible to include gemtuzumab ozogamicin in combination with intensive chemotherapy."( AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group.
Alonzo, TA; Arceci, RJ; Cooper, TM; Feusner, J; Franklin, J; Gamis, A; Gerbing, RB; Hirsch, B; Hurwitz, C; Iannone, R; Lavey, RS; Mathew, P; Meshinchi, S; Raimondi, SC; Smith, FO, 2012
)
0.38

Pharmacokinetics

ExcerptReferenceRelevance
"The aim was to investigate interspecies relationships between body weight (W) (kg) and various pharmacokinetic parameters for the anti-tumor agents amsacrine and its 4-methyl-5-(N-methylcarboxamide) analogue, CI-921, and examine which pharmacokinetic parameter, if any, might be used to predict the toxicity of these agents."( Pharmacokinetic and toxicity scaling of the antitumor agents amsacrine and CI-921, a new analogue, in mice, rats, rabbits, dogs, and humans.
Kim, SN; Paxton, JW; Whitfield, LR, 1990
)
0.72
" There was no significant difference between distribution and elimination half-life and mean residence time, but the apparent volume of distribution (means, 121 vs 45 l/kg) and clearance (means, 46."( Comparison of the pharmacokinetics and protein binding of the anticancer drug, amsacrine and a new analogue, N-5-dimethyl-9-[(2-methoxy-4-methylsulfonylamino)phenyl-amino] -4-acridinecarboxamide in rabbits.
Jurlina, JL; Paxton, JW, 1986
)
0.5
" The mean terminal plasma half-life for total 14C ranged from 34 hr in patients with normal organ function to 46 hr in patients with severe liver disease."( Human pharmacokinetics of a new acridine derivative, 4'-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992).
Benjamin, RS; Friedman, J; Gutterman, JU; Hall, SW; Legha, SS; Loo, TL, 1983
)
0.27
" The pharmacokinetic data served as a guideline for in vitro toxicity tests on clonogenic bone marrow cells."( Plasma and cellular pharmacokinetics of m-AMSA related to in vitro toxicity towards normal and leukemic clonogenic bone marrow cells (CFU-GM, CFU-L).
Brons, P; de Witte, T; Knops, G; Linssen, P; Wessels, H, 1993
)
0.29
" The intra-individual variation was much less, suggesting that dose adjustment based on pharmacokinetic data might be useful in the future."( In vitro cytotoxic drug activity and in vivo pharmacokinetics in childhood acute myeloid leukemia.
Frost, BM; Larsson, R; Liliemark, E; Lönnerholm, G; Nygren, P; Peterson, C, 1999
)
0.3
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
"04lh(-1)kg(-1)) and elimination half-life (6."( Formulation and pharmacokinetic evaluation of an asulacrine nanocrystalline suspension for intravenous delivery.
Baguley, BC; Ganta, S; Garg, S; Paxton, JW, 2009
)
0.35

Compound-Compound Interactions

Amsacrine (AMSA) can interact with bovine serum albumin (BSA) Effects of amsacrine in combination with other anticancer agents at ID80 were evaluated by cell growth assay using a human T-cell leukemia cell line (MOLT-3)

ExcerptReferenceRelevance
"Effects of amsacrine in combination with other anticancer agents at ID80 were evaluated by cell growth assay using a human T-cell leukemia cell line (MOLT-3)."( Effects of amsacrine in combination with other anticancer agents in human acute lymphoblastic leukemia cells in culture.
Akutsu, M; Inoue, Y; Kano, Y; Kasahara, T; Miura, Y; Sakamoto, S, 1991
)
1.06
" Further investigation of this drug combination in untreated patients with ANLL is warranted."( Comparative trial of cytarabine and thioguanine in combination with amsacrine or daunorubicin in patients with untreated acute nonlymphocytic leukemia: results of the L-16M protocol.
Andreeff, M; Arlin, ZA; Berman, E; Gaynor, J; Gee, T; Kempin, SJ; Mertelsmann, R; Miller, W; Nahmias, N; Reich, L, 1989
)
0.51
"A randomized phase II study of AMSA (amsacrine) alone and AMSA combined with DTIC (dacarbazine) was carried out in 31 and 39 patients with metastatic melanoma respectively."( Phase II study of AMSA alone and in combination with DTIC in patients with metastatic melanoma.
Benjamin, RS; Bodey, GP; Burgess, AM; Legha, SS; Polyzos, A, 1988
)
0.55
" When a single dose of AMSA was combined with a single dose of radiation (100 rad), there was a marked schedule dependence with the more effective sequence, especially if a 12 hour interval was chosen between doses, being AMSA followed by irradiation."( Effectiveness of AMSA alone or in combination with radiation on murine fibrosarcoma pulmonary nodules.
Grdina, DJ; Hunter, N; Jones, S,
)
0.13
" For the direct analysis of anticancer drug metabolites without their derivatization and extraction from biological fluids, high-pressure liquid chromatography (HPLC) in combination with field desorption (FD) mass spectrometry have developed as powerful methods."( Identification of metabolism pathways of anticancer drugs by high-pressure liquid chromatography in combination with field desorption mass spectrometry.
Przybylski, M, 1982
)
0.26
"5-Aza-2'-deoxycytidine combined with either amsacrine or idarubicin has been applied in a treatment protocol for patients with a relapse of acute myeloid or lymphocytic leukemia."( A randomized phase II study on the effects of 5-Aza-2'-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC Leukemia Cooperative Group phase II study (06893).
Archimbaud, E; Berneman, Z; Dardenne, M; Dohner, H; Jaksic, B; Jehn, U; Labar, B; Louwagie, EA; Muus, P; Stryckmans, P; Suciu, S; Tjean, M; Wijermans, P; Willemze, R; Zittoun, R, 1997
)
0.78
"6-fold when combined with ICRF-187 (B."( Improved targeting of brain tumors using dexrazoxane rescue of topoisomerase II combined with supralethal doses of etoposide and teniposide.
Holm, B; Jensen, PB; Sehested, M, 1998
)
0.3
"By research, it was found that the Amsacrine (AMSA) can interact with bovine serum albumin (BSA)."( Assisted sonodynamic damage of bovine serum albumin by metronidazole under ultrasonic irradiation combined with photosensitive antitumor drug-Amsacrine.
Guo, Y; Han, G; Ou, W; Wang, J; Wang, X; Xu, Y; Zhang, L; Zhang, X, 2010
)
0.84
"This trial determined that it is safe and feasible to include gemtuzumab ozogamicin in combination with intensive chemotherapy."( AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group.
Alonzo, TA; Arceci, RJ; Cooper, TM; Feusner, J; Franklin, J; Gamis, A; Gerbing, RB; Hirsch, B; Hurwitz, C; Iannone, R; Lavey, RS; Mathew, P; Meshinchi, S; Raimondi, SC; Smith, FO, 2012
)
0.38

Bioavailability

ExcerptReferenceRelevance
" The mean bioavailability for amsacrine was 50% +/- 17 (s."( The effect of food on the bioavailability and kinetics of the anticancer drug amsacrine and a new analogue, N-5-dimethyl-9-[(2-methoxy-4-methylsulphonylamino)phenylamino]-4 acridinecarboxamide in rabbits.
Paxton, JW, 1986
)
0.79
" Resistance was not due to a decrease in the bioavailability of the drug."( Development and characterization of a human myelogenous leukemia cell line resistant to 4'-(9-acridinylamino)-3-methanesulfon-m-anisidide.
Andersson, BS; Beran, M, 1987
)
0.27
" Preclinical studies demonstrated that amsalog is active orally: a clinical study of the oral bioavailability of amsalog was therefore performed."( A study of amsalog (CI-921) administered orally on a 5-day schedule, with bioavailability and pharmacokinetically guided dose escalation.
Carmichael, J; Clayton, K; Fyfe, D; Gardner, C; Halbert, G; Judson, I; Langley, RE; Newell, DR; Raynaud, F; Woll, PJ, 2002
)
0.31
" Doses were escalated further in subsequent cohorts, based on oral bioavailability and toxicity."( A study of amsalog (CI-921) administered orally on a 5-day schedule, with bioavailability and pharmacokinetically guided dose escalation.
Carmichael, J; Clayton, K; Fyfe, D; Gardner, C; Halbert, G; Judson, I; Langley, RE; Newell, DR; Raynaud, F; Woll, PJ, 2002
)
0.31
"Oral bioavailability of 50 mg/m2 amsalog was 34%."( A study of amsalog (CI-921) administered orally on a 5-day schedule, with bioavailability and pharmacokinetically guided dose escalation.
Carmichael, J; Clayton, K; Fyfe, D; Gardner, C; Halbert, G; Judson, I; Langley, RE; Newell, DR; Raynaud, F; Woll, PJ, 2002
)
0.31
" Its hydrochloride salt, 13a·HCl exhibited not only excellent water solubility (1049 μg/mL) but also a high oral bioavailability (57."( Discovery of 4-anilinofuro[2,3-b]quinoline derivatives as selective and orally active compounds against non-small-cell lung cancers.
Chen, YL; Chen, YW; Liang, CC; Lu, PJ; Tseng, CH; Tzeng, CC; Yang, CN; Yao, YC, 2011
)
0.37
" A standard MTT assay was used for cell bioavailability analysis."( Antiproliferative Effect of Novel Aminoacridine-based Compounds.
Gellerman, G; Gruzman, A; Levy, AR; Moskovitz, Y; Munder, A; Redko, B; Ruthstein, S, 2015
)
0.42

Dosage Studied

ExcerptRelevanceReference
" Bone marrow samples were taken 30 and 48 h post 0 h dosing in both the single and split dose studies."( Micronucleus induction by camptothecin and amsacrine in bone marrow of male and female CD-1 mice.
Holmström, M; Winters, V, 1992
)
0.55
" The patients were randomised at diagnosis to receive either three further courses of Ara-C (five days) and DNR (two days) in the same dosage or three courses of VP16 100 mg/m2 daily for five days and one dose of mAMSA of 200 mg/m2 as postremission consolidation."( Acute myeloid leukaemia: results of the New Zealand AML-1 study. The Leukaemia Study Group of the New Zealand Society for Haematology.
, 1991
)
0.28
" The recommended dosage in patients with solid tumors is 90-120 mg/m2 intravenously every 3-4 weeks."( Amsacrine (m-AMSA): a new antineoplastic agent. Pharmacology, clinical activity and toxicity.
Hornedo, J; Van Echo, DA,
)
1.57
" VP 16-213 was applied on days 1 and 5 by a 1-h infusion of 100 mg/m2 followed by a 23 h infusion, the dosage of which was escalated in three steps from 110 mg/m2 over 200 mg/m2 to 230 mg/m2 in subsequent patients."( Treatment of refractory acute myeloid leukemia with mAMSA and VP 16-213 in combination: results of a clinical phase I/II study.
Achterrath, W; Büchner, T; Hiddemann, W; Preusser, P; Urbanitz, D,
)
0.13
" We observed that inhibitors of both type I and II topoisomerases induced high levels of sister chromatid exchanges at 10(-6) M, and that the dose-response curves of these drugs were very similar."( Induction of sister chromatid exchanges by inhibitors of topoisomerases.
Jacobson-Kram, D; Lim, M; Liu, LF; Williams, JR, 1986
)
0.27
" This study suggests that oral dosing may be a possible alternative route for the administration of these anticancer agents."( The effect of food on the bioavailability and kinetics of the anticancer drug amsacrine and a new analogue, N-5-dimethyl-9-[(2-methoxy-4-methylsulphonylamino)phenylamino]-4 acridinecarboxamide in rabbits.
Paxton, JW, 1986
)
0.5
" Here we report dose-response data on the mutagenicity and toxicity of m-AMSA in T4 rFC11."( Mutagenicity of topoisomerase-active agents in bacteriophage T4.
DeMarini, DM; Lawrence, BK, 1988
)
0.27
" A single dose of CY or four consecutive daily doses of AMSA produced increased survival in leukemic rats, with a positive-slope dose-response curve up to the maximum tolerated dose (MTD)."( Hydroxyurea potentiation of the antineoplastic activity of cyclophosphamide and 4'-(9-acridinylamino)methanesulfon-M-anisidide (AMSA) in the brown Norway rat myelocytic leukemia model.
Cordel, K; Holm, C; Vaughan, WP, 1989
)
0.28
" Sharp plateaus in the VpmR-5 dose-response curves for Adriamycin-induced DNA strand breaks and cytotoxicity appear to be related to interference with type II topoisomerase-mediated cleavage of DNA at high concentrations of the intercalator."( Cross-resistance to intercalating agents in an epipodophyllotoxin-resistant Chinese hamster ovary cell line: evidence for a common intracellular target.
Glisson, B; Gupta, R; Hodges, P; Ross, W, 1986
)
0.27
" The results of the dose-response study indicate that m-AMSA has an acute moderate negative inotropic effect."( The effects of m-AMSA on rat isolated heart.
Gotsman, MS; Hasin, Y; Merkin, MS; Shefer, A; Shinar, E,
)
0.13
" Although intraperitoneal dosage was superior to intravenous or oral dosage for the treatment of intraperitoneally inoculated P388 leukaemia, all three routes of administration provided similar results with intravenously inoculated Lewis lung or subcutaneously implanted P388 cells."( Schedule dependence of activity of the amsacrine analogue CI-921 towards P388 leukaemia and Lewis lung carcinoma.
Baguley, BC; Grimwade, CD; Kernohan, AR, 1985
)
0.54
" push in a dosage of 150 mg/m2 for 5 days."( 4'-(9-acridinylamino)methane-sulfon-m-anisidide (m-AMSA) and 5-azacytidine (AZA) in the treatment of relapsed adult acute leukemia.
Brodsky, I; Bulova, S; Conroy, JF; Kahn, SB; Lebedda, J; Sklaroff, R, 1983
)
0.27
" Dosage was 75 mg/m2, iv, day 1-7, all 3-5 weeks."( [Phase II study of AMSA in adults with acute therapy-refractory leukemias].
Engelhardt, R; Fiebig, HH; Henss, H; Hoelzer, D; Link, H; Pralle, H; Schmitz, R, 1983
)
0.27
"In a phase I study the combination of AMSA and etoposide was applied to 12 patients with intensively pretreated, refractory AML to evaluate the basis for a subsequent phase II study in terms of drug dosage and timing."( [Combined therapy with AMSA and etoposide (VP 16-213) in refractory acute myeloid leukemia. A phase I study].
Achterrath, W; Balleisen, L; Büchner, T; Hiddemann, W; Kirchhof, B; Preusser, P; Stenzinger, W; Urbanitz, D, 1984
)
0.27
"Patients with acute leukemia in relapse were given 5'-(9-acridinylamino)methanesulfon-m-anisidide at a dosage of 75 to 200 mg/sq m as a daily bolus infusion of 5 consecutive days."( Phase I and II trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide in patients with acute leukemia.
Arlin, ZA; Clarkson, BD; Gee, TS; Howard, J; Kempin, SJ; Sklaroff, RB; Young, CW, 1980
)
0.26
" Although this schedule shows high activity in relapsed small-cell lung cancer and lymphoma, it is associated with significant toxicity (around one-third of patients experience grade III/IV leukopenia or neutropenia), which may be related to the observation that the etoposide dose delivered per course in these studies is higher than that obtained with standard dosing over 3-5 days."( Schedule-dependent topoisomerase II-inhibiting drugs.
Joel, SP; Slevin, ML, 1994
)
0.29
" This study was conducted to assess the subchronic toxicity of amsacrine in rats following a cyclic clinical dosing regimen and as a range-finding experiment for a subsequent carcinogenicity bioassay."( Subchronic intravenous toxicity of the antineoplastic drug, amsacrine, in male Wistar rats.
Graziano, MJ; McKenna, MJ; Pegg, DG; Watkins, JR, 1996
)
0.78
" This cycle of dosing and recovery was repeated a total of six times."( Carcinogenicity of the anticancer topoisomerase inhibitor, amsacrine, in Wistar rats.
Courtney, CL; Gough, AW; Graziano, MJ; Kheoh, T; Meierhenry, EF; Pegg, DG, 1996
)
0.54
" Recombinant GM-CSF was initially administered at standard dosage (5 micrograms/kg/day) until a white blood cell count > or = 2 x 10(9)/L was achieved on two consecutive examinations, and thereafter at a low dose (1 microgram/kg/day) for 5 to 9 months."( Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells.
Andrizzi, C; Carlo-Stella, C; Garau, D; Mandelli, F; Meloni, G; Montefusco, E; Regazzi, E; Rizzoli, V; Savoldo, B; Vignetti, M,
)
0.13
" Southern analysis of topo IIbeta shows no differences in gene dosage between the two cell lines but does show differences in the restriction patterns."( Absence of topoisomerase IIbeta in an amsacrine-resistant human leukemia cell line with mutant topoisomerase IIalpha.
Ganapathi, R; Herzog, CE; Holmes, KA; Tuschong, LM; Zwelling, LA, 1998
)
0.57
" Given the increased number of early treatment-related deaths, future treatment protocols should aim to reduce chemotherapy dosage or intensity whilst maintaining low rates of resistant and recurrent disease."( Treatment for myeloid leukaemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials.
de Graaf, SS; Gibson, BE; Hann, IM; Hills, RK; O'Marcaigh, A; Rao, A; Stiller, C; Webb, DK; Wheatley, K, 2006
)
0.33
" Based on these results, male MutaMouse mice (5 per group) were dosed daily with bleomycin (50 mg/kg bw) for 5 days or with camptothecin (5 mg/kg bw) for 2 days."( Is MutaMouse insensitive to clastogens?
Bradford, A; Brockhurst, K; Lynch, AM; Mahabir, AG; Rees, RW; van Benthem, J; van Steeg, H, 2008
)
0.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitorA topoisomerase inhibitor that inhibits DNA topoisomerase (ATP-hydrolysing), EC 5.99.1.3 (also known as topoisomerase II and as DNA gyrase), which catalyses ATP-dependent breakage of both strands of DNA, passage of the unbroken strands through the breaks, and rejoining of the broken strands.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
sulfonamideAn amide of a sulfonic acid RS(=O)2NR'2.
acridines
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (67)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, HADH2 proteinHomo sapiens (human)Potency31.62280.025120.237639.8107AID886; AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency31.62280.025120.237639.8107AID886; AID893
thioredoxin reductaseRattus norvegicus (Norway rat)Potency23.48770.100020.879379.4328AID488773; AID588453; AID588456
ATAD5 protein, partialHomo sapiens (human)Potency17.58140.004110.890331.5287AID493106; AID493107
Fumarate hydrataseHomo sapiens (human)Potency4.46680.00308.794948.0869AID1347053
USP1 protein, partialHomo sapiens (human)Potency0.56230.031637.5844354.8130AID504865
GLS proteinHomo sapiens (human)Potency1.00000.35487.935539.8107AID624146
PPM1D proteinHomo sapiens (human)Potency26.21230.00529.466132.9993AID1347411
ThrombopoietinHomo sapiens (human)Potency2.51190.02517.304831.6228AID917; AID918
signal transducer and activator of transcription 6, interleukin-4 inducedHomo sapiens (human)Potency25.11892.51199.410115.8489AID922; AID934; AID935
DNA polymerase III, partialBacillus subtilisPotency29.93491.062114.152826.6795AID485295
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency5.01190.00137.762544.6684AID914; AID915
thyroid stimulating hormone receptorHomo sapiens (human)Potency39.81070.001318.074339.8107AID926; AID938
regulator of G-protein signaling 4Homo sapiens (human)Potency37.68580.531815.435837.6858AID504845
polyproteinZika virusPotency4.46680.00308.794948.0869AID1347053
alpha-galactosidaseHomo sapiens (human)Potency44.66844.466818.391635.4813AID992
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency11.91730.035520.977089.1251AID504332
heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa)Homo sapiens (human)Potency58.47890.016525.307841.3999AID602332
cellular tumor antigen p53 isoform aHomo sapiens (human)Potency4.47160.316212.443531.6228AID902; AID924
cytochrome P450 2C9 precursorHomo sapiens (human)Potency12.58930.00636.904339.8107AID883
D(1A) dopamine receptorHomo sapiens (human)Potency0.64280.02245.944922.3872AID488982; AID488983
chromobox protein homolog 1Homo sapiens (human)Potency79.43280.006026.168889.1251AID488953
flap endonuclease 1Homo sapiens (human)Potency5.97280.133725.412989.1251AID588795
ras-related protein Rab-9AHomo sapiens (human)Potency73.07800.00022.621531.4954AID485297
serine/threonine-protein kinase mTOR isoform 1Homo sapiens (human)Potency1.44730.00378.618923.2809AID2660; AID2667; AID2668
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency19.95260.031610.279239.8107AID884; AID885
caspase-1 isoform alpha precursorHomo sapiens (human)Potency15.84890.000311.448431.6228AID900
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency8.15480.00106.000935.4813AID943; AID944
lethal factor (plasmid)Bacillus anthracis str. A2012Potency12.58930.020010.786931.6228AID912
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Interferon betaHomo sapiens (human)Potency26.21230.00339.158239.8107AID1347411
Integrin beta-3Homo sapiens (human)Potency1.00000.316211.415731.6228AID924
Integrin alpha-IIbHomo sapiens (human)Potency1.00000.316211.415731.6228AID924
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency12.58930.00638.235039.8107AID883
D(1A) dopamine receptorSus scrofa (pig)Potency3.68980.00378.108123.2809AID2667
Caspase-7Homo sapiens (human)Potency15.84893.981118.585631.6228AID889
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency0.87780.009610.525035.4813AID1479145; AID1479148
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Ataxin-2Homo sapiens (human)Potency0.35480.011912.222168.7989AID588378
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 22 member 1 Homo sapiens (human)IC50 (µMol)5.00000.21005.553710.0000AID386625
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)7.43000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)133.00000.11007.190310.0000AID1473738
Cytochrome P450 2D6Homo sapiens (human)IC50 (µMol)10.35000.00002.015110.0000AID240619
Cytochrome P450 2D6Homo sapiens (human)Ki7.50000.00011.19868.0000AID238250
DNA topoisomerase 2-alphaHomo sapiens (human)IC50 (µMol)8.98000.48004.35649.9400AID1695165; AID351114; AID57198
5-hydroxytryptamine receptor 7Cavia porcellus (domestic guinea pig)IC50 (µMol)5.00002.03005.53139.9000AID386625
Aldehyde oxidase 1Oryctolagus cuniculus (rabbit)Ki0.06000.06000.06000.0600AID547842
DNA topoisomerase 2-betaHomo sapiens (human)IC50 (µMol)1.88000.03002.77167.8000AID1384115; AID57198
Aldehyde oxidaseHomo sapiens (human)IC50 (µMol)3.20000.00230.63203.3000AID547838
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)IC50 (µMol)0.20950.00091.901410.0000AID386536; AID576612
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
Aldehyde oxidase 1 Rattus norvegicus (Norway rat)IC50 (µMol)6.40000.19001.90606.4000AID547840
Aldehyde oxidase 1 Rattus norvegicus (Norway rat)Ki3.00000.03001.11003.0000AID547840
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
DNA topoisomerase 2-alphaHomo sapiens (human)EC50 (µMol)0.72000.72001.29003.0000AID211292; AID57063
DNA topoisomerase 2-betaHomo sapiens (human)EC50 (µMol)0.72000.72001.29003.0000AID211292; AID57063
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
DNA topoisomerase 2-alphaHomo sapiens (human)Activity8.50008.50008.50008.5000AID1434039
DNA topoisomerase 2-alphaHomo sapiens (human)IC90 (µMol)33.00001.10001.10001.1000AID211122; AID57199
DNA topoisomerase 2-betaHomo sapiens (human)IC90 (µMol)33.00001.10001.10001.1000AID211122; AID57199
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (247)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processSolute carrier family 22 member 1 Homo sapiens (human)
neurotransmitter transportSolute carrier family 22 member 1 Homo sapiens (human)
serotonin transportSolute carrier family 22 member 1 Homo sapiens (human)
establishment or maintenance of transmembrane electrochemical gradientSolute carrier family 22 member 1 Homo sapiens (human)
organic cation transportSolute carrier family 22 member 1 Homo sapiens (human)
quaternary ammonium group transportSolute carrier family 22 member 1 Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 1 Homo sapiens (human)
monoamine transportSolute carrier family 22 member 1 Homo sapiens (human)
putrescine transportSolute carrier family 22 member 1 Homo sapiens (human)
spermidine transportSolute carrier family 22 member 1 Homo sapiens (human)
acetylcholine transportSolute carrier family 22 member 1 Homo sapiens (human)
dopamine transportSolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine transportSolute carrier family 22 member 1 Homo sapiens (human)
thiamine transportSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 1 Homo sapiens (human)
epinephrine transportSolute carrier family 22 member 1 Homo sapiens (human)
serotonin uptakeSolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine uptakeSolute carrier family 22 member 1 Homo sapiens (human)
thiamine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
metanephric proximal tubule developmentSolute carrier family 22 member 1 Homo sapiens (human)
purine-containing compound transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
dopamine uptakeSolute carrier family 22 member 1 Homo sapiens (human)
monoatomic cation transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 22 member 1 Homo sapiens (human)
(R)-carnitine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
acyl carnitine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
spermidine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
cellular detoxificationSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transport across blood-brain barrierSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
negative regulation of low-density lipoprotein receptor activityIntegrin beta-3Homo sapiens (human)
positive regulation of protein phosphorylationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
cell-substrate junction assemblyIntegrin beta-3Homo sapiens (human)
cell adhesionIntegrin beta-3Homo sapiens (human)
cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
integrin-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
embryo implantationIntegrin beta-3Homo sapiens (human)
blood coagulationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of gene expressionIntegrin beta-3Homo sapiens (human)
negative regulation of macrophage derived foam cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast migrationIntegrin beta-3Homo sapiens (human)
negative regulation of lipid storageIntegrin beta-3Homo sapiens (human)
response to activityIntegrin beta-3Homo sapiens (human)
smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
platelet activationIntegrin beta-3Homo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
cell-substrate adhesionIntegrin beta-3Homo sapiens (human)
activation of protein kinase activityIntegrin beta-3Homo sapiens (human)
negative regulation of lipid transportIntegrin beta-3Homo sapiens (human)
regulation of protein localizationIntegrin beta-3Homo sapiens (human)
regulation of actin cytoskeleton organizationIntegrin beta-3Homo sapiens (human)
cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of osteoblast proliferationIntegrin beta-3Homo sapiens (human)
heterotypic cell-cell adhesionIntegrin beta-3Homo sapiens (human)
substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
tube developmentIntegrin beta-3Homo sapiens (human)
wound healing, spreading of epidermal cellsIntegrin beta-3Homo sapiens (human)
cellular response to platelet-derived growth factor stimulusIntegrin beta-3Homo sapiens (human)
apolipoprotein A-I-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
wound healingIntegrin beta-3Homo sapiens (human)
apoptotic cell clearanceIntegrin beta-3Homo sapiens (human)
regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
positive regulation of angiogenesisIntegrin beta-3Homo sapiens (human)
positive regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
symbiont entry into host cellIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast proliferationIntegrin beta-3Homo sapiens (human)
mesodermal cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationIntegrin beta-3Homo sapiens (human)
negative regulation of lipoprotein metabolic processIntegrin beta-3Homo sapiens (human)
negative chemotaxisIntegrin beta-3Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosolIntegrin beta-3Homo sapiens (human)
regulation of serotonin uptakeIntegrin beta-3Homo sapiens (human)
angiogenesis involved in wound healingIntegrin beta-3Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeIntegrin beta-3Homo sapiens (human)
platelet aggregationIntegrin beta-3Homo sapiens (human)
cellular response to mechanical stimulusIntegrin beta-3Homo sapiens (human)
cellular response to xenobiotic stimulusIntegrin beta-3Homo sapiens (human)
positive regulation of glomerular mesangial cell proliferationIntegrin beta-3Homo sapiens (human)
blood coagulation, fibrin clot formationIntegrin beta-3Homo sapiens (human)
maintenance of postsynaptic specialization structureIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor internalizationIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor diffusion trappingIntegrin beta-3Homo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
positive regulation of adenylate cyclase-inhibiting opioid receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
regulation of trophoblast cell migrationIntegrin beta-3Homo sapiens (human)
regulation of extracellular matrix organizationIntegrin beta-3Homo sapiens (human)
cellular response to insulin-like growth factor stimulusIntegrin beta-3Homo sapiens (human)
negative regulation of endothelial cell apoptotic processIntegrin beta-3Homo sapiens (human)
positive regulation of T cell migrationIntegrin beta-3Homo sapiens (human)
cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of leukocyte migrationIntegrin alpha-IIbHomo sapiens (human)
cell-matrix adhesionIntegrin alpha-IIbHomo sapiens (human)
integrin-mediated signaling pathwayIntegrin alpha-IIbHomo sapiens (human)
angiogenesisIntegrin alpha-IIbHomo sapiens (human)
cell-cell adhesionIntegrin alpha-IIbHomo sapiens (human)
cell adhesion mediated by integrinIntegrin alpha-IIbHomo sapiens (human)
xenobiotic metabolic processCytochrome P450 2D6Homo sapiens (human)
steroid metabolic processCytochrome P450 2D6Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2D6Homo sapiens (human)
estrogen metabolic processCytochrome P450 2D6Homo sapiens (human)
coumarin metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid catabolic processCytochrome P450 2D6Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2D6Homo sapiens (human)
isoquinoline alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2D6Homo sapiens (human)
retinol metabolic processCytochrome P450 2D6Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2D6Homo sapiens (human)
negative regulation of bindingCytochrome P450 2D6Homo sapiens (human)
oxidative demethylationCytochrome P450 2D6Homo sapiens (human)
negative regulation of cellular organofluorine metabolic processCytochrome P450 2D6Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 2D6Homo sapiens (human)
hematopoietic progenitor cell differentiationDNA topoisomerase 2-alphaHomo sapiens (human)
DNA topological changeDNA topoisomerase 2-alphaHomo sapiens (human)
DNA ligationDNA topoisomerase 2-alphaHomo sapiens (human)
DNA damage responseDNA topoisomerase 2-alphaHomo sapiens (human)
chromosome segregationDNA topoisomerase 2-alphaHomo sapiens (human)
female meiotic nuclear divisionDNA topoisomerase 2-alphaHomo sapiens (human)
apoptotic chromosome condensationDNA topoisomerase 2-alphaHomo sapiens (human)
embryonic cleavageDNA topoisomerase 2-alphaHomo sapiens (human)
regulation of circadian rhythmDNA topoisomerase 2-alphaHomo sapiens (human)
positive regulation of apoptotic processDNA topoisomerase 2-alphaHomo sapiens (human)
positive regulation of single stranded viral RNA replication via double stranded DNA intermediateDNA topoisomerase 2-alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIDNA topoisomerase 2-alphaHomo sapiens (human)
rhythmic processDNA topoisomerase 2-alphaHomo sapiens (human)
negative regulation of DNA duplex unwindingDNA topoisomerase 2-alphaHomo sapiens (human)
resolution of meiotic recombination intermediatesDNA topoisomerase 2-alphaHomo sapiens (human)
sister chromatid segregationDNA topoisomerase 2-alphaHomo sapiens (human)
proteolysisCaspase-7Homo sapiens (human)
apoptotic processCaspase-7Homo sapiens (human)
heart developmentCaspase-7Homo sapiens (human)
response to UVCaspase-7Homo sapiens (human)
protein processingCaspase-7Homo sapiens (human)
protein catabolic processCaspase-7Homo sapiens (human)
defense response to bacteriumCaspase-7Homo sapiens (human)
fibroblast apoptotic processCaspase-7Homo sapiens (human)
striated muscle cell differentiationCaspase-7Homo sapiens (human)
neuron apoptotic processCaspase-7Homo sapiens (human)
protein maturationCaspase-7Homo sapiens (human)
lymphocyte apoptotic processCaspase-7Homo sapiens (human)
cellular response to lipopolysaccharideCaspase-7Homo sapiens (human)
cellular response to staurosporineCaspase-7Homo sapiens (human)
execution phase of apoptosisCaspase-7Homo sapiens (human)
positive regulation of plasma membrane repairCaspase-7Homo sapiens (human)
positive regulation of neuron apoptotic processCaspase-7Homo sapiens (human)
neuron migrationDNA topoisomerase 2-betaHomo sapiens (human)
DNA topological changeDNA topoisomerase 2-betaHomo sapiens (human)
axonogenesisDNA topoisomerase 2-betaHomo sapiens (human)
B cell differentiationDNA topoisomerase 2-betaHomo sapiens (human)
forebrain developmentDNA topoisomerase 2-betaHomo sapiens (human)
positive regulation of single stranded viral RNA replication via double stranded DNA intermediateDNA topoisomerase 2-betaHomo sapiens (human)
cellular response to hydrogen peroxideDNA topoisomerase 2-betaHomo sapiens (human)
cellular response to ATPDNA topoisomerase 2-betaHomo sapiens (human)
cellular senescenceDNA topoisomerase 2-betaHomo sapiens (human)
positive regulation of double-strand break repair via nonhomologous end joiningDNA topoisomerase 2-betaHomo sapiens (human)
sister chromatid segregationDNA topoisomerase 2-betaHomo sapiens (human)
resolution of meiotic recombination intermediatesDNA topoisomerase 2-betaHomo sapiens (human)
lipid metabolic processAldehyde oxidaseHomo sapiens (human)
xenobiotic metabolic processAldehyde oxidaseHomo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by hormonePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion homeostasisPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cardiac muscle contractionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane depolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion import across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (104)

Processvia Protein(s)Taxonomy
acetylcholine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
neurotransmitter transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
dopamine:sodium symporter activitySolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine:sodium symporter activitySolute carrier family 22 member 1 Homo sapiens (human)
protein bindingSolute carrier family 22 member 1 Homo sapiens (human)
monoamine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
secondary active organic cation transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
organic cation transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
pyrimidine nucleoside transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
thiamine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
putrescine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
spermidine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
quaternary ammonium group transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
toxin transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
identical protein bindingSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
(R)-carnitine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
fibroblast growth factor bindingIntegrin beta-3Homo sapiens (human)
C-X3-C chemokine bindingIntegrin beta-3Homo sapiens (human)
insulin-like growth factor I bindingIntegrin beta-3Homo sapiens (human)
neuregulin bindingIntegrin beta-3Homo sapiens (human)
virus receptor activityIntegrin beta-3Homo sapiens (human)
fibronectin bindingIntegrin beta-3Homo sapiens (human)
protease bindingIntegrin beta-3Homo sapiens (human)
protein disulfide isomerase activityIntegrin beta-3Homo sapiens (human)
protein kinase C bindingIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor bindingIntegrin beta-3Homo sapiens (human)
integrin bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin beta-3Homo sapiens (human)
coreceptor activityIntegrin beta-3Homo sapiens (human)
enzyme bindingIntegrin beta-3Homo sapiens (human)
identical protein bindingIntegrin beta-3Homo sapiens (human)
vascular endothelial growth factor receptor 2 bindingIntegrin beta-3Homo sapiens (human)
metal ion bindingIntegrin beta-3Homo sapiens (human)
cell adhesion molecule bindingIntegrin beta-3Homo sapiens (human)
extracellular matrix bindingIntegrin beta-3Homo sapiens (human)
fibrinogen bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin alpha-IIbHomo sapiens (human)
identical protein bindingIntegrin alpha-IIbHomo sapiens (human)
metal ion bindingIntegrin alpha-IIbHomo sapiens (human)
extracellular matrix bindingIntegrin alpha-IIbHomo sapiens (human)
molecular adaptor activityIntegrin alpha-IIbHomo sapiens (human)
fibrinogen bindingIntegrin alpha-IIbHomo sapiens (human)
integrin bindingIntegrin alpha-IIbHomo sapiens (human)
monooxygenase activityCytochrome P450 2D6Homo sapiens (human)
iron ion bindingCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activityCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2D6Homo sapiens (human)
heme bindingCytochrome P450 2D6Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
magnesium ion bindingDNA topoisomerase 2-alphaHomo sapiens (human)
DNA bindingDNA topoisomerase 2-alphaHomo sapiens (human)
chromatin bindingDNA topoisomerase 2-alphaHomo sapiens (human)
RNA bindingDNA topoisomerase 2-alphaHomo sapiens (human)
DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) activityDNA topoisomerase 2-alphaHomo sapiens (human)
protein kinase C bindingDNA topoisomerase 2-alphaHomo sapiens (human)
protein bindingDNA topoisomerase 2-alphaHomo sapiens (human)
ATP bindingDNA topoisomerase 2-alphaHomo sapiens (human)
ATP-dependent activity, acting on DNADNA topoisomerase 2-alphaHomo sapiens (human)
DNA binding, bendingDNA topoisomerase 2-alphaHomo sapiens (human)
protein homodimerization activityDNA topoisomerase 2-alphaHomo sapiens (human)
ubiquitin bindingDNA topoisomerase 2-alphaHomo sapiens (human)
protein heterodimerization activityDNA topoisomerase 2-alphaHomo sapiens (human)
RNA bindingCaspase-7Homo sapiens (human)
aspartic-type endopeptidase activityCaspase-7Homo sapiens (human)
cysteine-type endopeptidase activityCaspase-7Homo sapiens (human)
protein bindingCaspase-7Homo sapiens (human)
peptidase activityCaspase-7Homo sapiens (human)
cysteine-type peptidase activityCaspase-7Homo sapiens (human)
cysteine-type endopeptidase activity involved in apoptotic processCaspase-7Homo sapiens (human)
cysteine-type endopeptidase activity involved in execution phase of apoptosisCaspase-7Homo sapiens (human)
DNA bindingDNA topoisomerase 2-betaHomo sapiens (human)
chromatin bindingDNA topoisomerase 2-betaHomo sapiens (human)
DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) activityDNA topoisomerase 2-betaHomo sapiens (human)
protein bindingDNA topoisomerase 2-betaHomo sapiens (human)
ATP bindingDNA topoisomerase 2-betaHomo sapiens (human)
ribonucleoprotein complex bindingDNA topoisomerase 2-betaHomo sapiens (human)
metal ion bindingDNA topoisomerase 2-betaHomo sapiens (human)
aldehyde oxidase activityAldehyde oxidaseHomo sapiens (human)
iron ion bindingAldehyde oxidaseHomo sapiens (human)
identical protein bindingAldehyde oxidaseHomo sapiens (human)
protein homodimerization activityAldehyde oxidaseHomo sapiens (human)
molybdopterin cofactor bindingAldehyde oxidaseHomo sapiens (human)
flavin adenine dinucleotide bindingAldehyde oxidaseHomo sapiens (human)
NAD bindingAldehyde oxidaseHomo sapiens (human)
2 iron, 2 sulfur cluster bindingAldehyde oxidaseHomo sapiens (human)
FAD bindingAldehyde oxidaseHomo sapiens (human)
transcription cis-regulatory region bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ubiquitin protein ligase bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
identical protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein homodimerization activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
C3HC4-type RING finger domain bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
scaffold protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (67)

Processvia Protein(s)Taxonomy
plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
membraneSolute carrier family 22 member 1 Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
lateral plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
presynapseSolute carrier family 22 member 1 Homo sapiens (human)
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
glutamatergic synapseIntegrin beta-3Homo sapiens (human)
nucleusIntegrin beta-3Homo sapiens (human)
nucleoplasmIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin beta-3Homo sapiens (human)
cell-cell junctionIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
external side of plasma membraneIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
apical plasma membraneIntegrin beta-3Homo sapiens (human)
platelet alpha granule membraneIntegrin beta-3Homo sapiens (human)
lamellipodium membraneIntegrin beta-3Homo sapiens (human)
filopodium membraneIntegrin beta-3Homo sapiens (human)
microvillus membraneIntegrin beta-3Homo sapiens (human)
ruffle membraneIntegrin beta-3Homo sapiens (human)
integrin alphav-beta3 complexIntegrin beta-3Homo sapiens (human)
melanosomeIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
postsynaptic membraneIntegrin beta-3Homo sapiens (human)
extracellular exosomeIntegrin beta-3Homo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin beta-3Homo sapiens (human)
glycinergic synapseIntegrin beta-3Homo sapiens (human)
integrin complexIntegrin beta-3Homo sapiens (human)
protein-containing complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-PKCalpha complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-IGF-1-IGF1R complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-HMGB1 complexIntegrin beta-3Homo sapiens (human)
receptor complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-vitronectin complexIntegrin beta-3Homo sapiens (human)
alpha9-beta1 integrin-ADAM8 complexIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin alpha-IIbHomo sapiens (human)
focal adhesionIntegrin alpha-IIbHomo sapiens (human)
cell surfaceIntegrin alpha-IIbHomo sapiens (human)
platelet alpha granule membraneIntegrin alpha-IIbHomo sapiens (human)
extracellular exosomeIntegrin alpha-IIbHomo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin alpha-IIbHomo sapiens (human)
blood microparticleIntegrin alpha-IIbHomo sapiens (human)
integrin complexIntegrin alpha-IIbHomo sapiens (human)
external side of plasma membraneIntegrin alpha-IIbHomo sapiens (human)
mitochondrionCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulumCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2D6Homo sapiens (human)
cytoplasmCytochrome P450 2D6Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2D6Homo sapiens (human)
nucleolusDNA topoisomerase 2-alphaHomo sapiens (human)
nuclear chromosomeDNA topoisomerase 2-alphaHomo sapiens (human)
centrioleDNA topoisomerase 2-alphaHomo sapiens (human)
chromosome, centromeric regionDNA topoisomerase 2-alphaHomo sapiens (human)
condensed chromosomeDNA topoisomerase 2-alphaHomo sapiens (human)
male germ cell nucleusDNA topoisomerase 2-alphaHomo sapiens (human)
nucleusDNA topoisomerase 2-alphaHomo sapiens (human)
nucleoplasmDNA topoisomerase 2-alphaHomo sapiens (human)
nucleolusDNA topoisomerase 2-alphaHomo sapiens (human)
cytoplasmDNA topoisomerase 2-alphaHomo sapiens (human)
DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) complexDNA topoisomerase 2-alphaHomo sapiens (human)
protein-containing complexDNA topoisomerase 2-alphaHomo sapiens (human)
ribonucleoprotein complexDNA topoisomerase 2-alphaHomo sapiens (human)
nucleusDNA topoisomerase 2-alphaHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
extracellular spaceCaspase-7Homo sapiens (human)
nucleusCaspase-7Homo sapiens (human)
cytoplasmCaspase-7Homo sapiens (human)
cytosolCaspase-7Homo sapiens (human)
nucleusCaspase-7Homo sapiens (human)
nucleoplasmCaspase-7Homo sapiens (human)
cytosolCaspase-7Homo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
nucleolusDNA topoisomerase 2-betaHomo sapiens (human)
heterochromatinDNA topoisomerase 2-betaHomo sapiens (human)
nucleusDNA topoisomerase 2-betaHomo sapiens (human)
nucleoplasmDNA topoisomerase 2-betaHomo sapiens (human)
nucleolusDNA topoisomerase 2-betaHomo sapiens (human)
cytosolDNA topoisomerase 2-betaHomo sapiens (human)
ribonucleoprotein complexDNA topoisomerase 2-betaHomo sapiens (human)
nucleusDNA topoisomerase 2-betaHomo sapiens (human)
cytosolAldehyde oxidaseHomo sapiens (human)
extracellular exosomeAldehyde oxidaseHomo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
perinuclear region of cytoplasmPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (553)

Assay IDTitleYearJournalArticle
AID1347412qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID427933Inhibition of human recombinant topoisomerase 2 relaxation activity assessed as supercoiled pBR322 DNA at 8 uM2009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
Benzothiopyranoindole-based antiproliferative agents: synthesis, cytotoxicity, nucleic acids interaction, and topoisomerases inhibition properties.
AID225778Inhibitory concentration against ethidium in DNA-binding assay with [poly(dG-dC)]2 (synthetic oligonucleotide)1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Novel acridine-triazenes as prototype combilexins: synthesis, DNA binding, and biological activity.
AID152884In vivo for antitumor activity against P388 leukemia1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Potential antitumor agents. 47. 3'-Methylamino analogues of amsacrine with in vivo solid tumor activity.
AID1272962Inhibition of Mycobacterium tuberculosis DNA topoisomerase 12016Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4
Development of acridine derivatives as selective Mycobacterium tuberculosis DNA gyrase inhibitors.
AID35545Ability to block cleavage of AG/CT site in AluI enzyme with the test compound, DNA ratio 1(no. of sites=16); - = no activation1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Properties of the nucleic acid photoaffinity labeling agent 3-azidoamsacrine.
AID365818Cytotoxicity against human Jurkat cells by Hoechst test2008Bioorganic & medicinal chemistry, Aug-15, Volume: 16, Issue:16
Design, synthesis and preliminary biological evaluation of acridine compounds as potential agents for a combined targeted chemo-radionuclide therapy approach to melanoma.
AID153028Optimal dose required to inhibit the P388 intraperitoneal administration.1987Journal of medicinal chemistry, Sep, Volume: 30, Issue:9
Potential antitumor agents. 52. Carbamate analogues of amsacrine with in vivo activity against multidrug-resistant P388 leukemia.
AID576614Growth inhibition in human A431 cells after 72 hrs by trypan blue assay2011Bioorganic & medicinal chemistry, Feb-01, Volume: 19, Issue:3
Benzoquinazoline derivatives as new agents affecting DNA processing.
AID54658Inhibitory concentration against ethidium in DNA-binding assay1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Novel acridine-triazenes as prototype combilexins: synthesis, DNA binding, and biological activity.
AID382900Cytotoxicity against human CCRF-CEM cells after 72 hrs2008Bioorganic & medicinal chemistry, Apr-15, Volume: 16, Issue:8
DNA threading bis(9-aminoacridine-4-carboxamides): effects of piperidine sidechains on DNA binding, cytotoxicity and cell cycle arrest.
AID396407Antiproliferative activity against human HT-29 cells after 48 hrs by SRB assay2008European journal of medicinal chemistry, Nov, Volume: 43, Issue:11
Novel imidazo[1,2-a]naphthyridinic systems (part 1): synthesis, antiproliferative and DNA-intercalating activities.
AID1396994Binding affinity to calf thymus DNA by UV-Vis absorption spectral analysis2018Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14
Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID108703The compound (5 mg/kg, ip) was tested for change in average weight of BDF2 mice bearing E0771 mammary adenocarcinoma1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
9-substituted acridine derivatives with long half-life and potent antitumor activity: synthesis and structure-activity relationships.
AID347895Cytotoxicity against human 2008 cells after 72 hrs by MTT assay2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Synthesis and antitumor activity of novel amsacrine analogs: the critical role of the acridine moiety in determining their biological activity.
AID55008Association constant measured for binding towards poly[d(A-T)] of DNA in calf thymus1981Journal of medicinal chemistry, May, Volume: 24, Issue:5
Potential antitumor agents. 35. Quantitative relationships between antitumor (L1210) potency and DNA binding for 4'-(9-acridinylamino)methanesulfon-m-anisidide analogues.
AID1453383Antiproliferative activity against human K562 cells after 48 hrs by MTT assay2017Bioorganic & medicinal chemistry, 07-01, Volume: 25, Issue:13
Synthesis and biological research of novel azaacridine derivatives as potent DNA-binding ligands and topoisomerase II inhibitors.
AID347894Cytotoxicity against human A549 cells after 72 hrs by MTT assay2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Synthesis and antitumor activity of novel amsacrine analogs: the critical role of the acridine moiety in determining their biological activity.
AID1609095Selectivity index, ratio of CC50 for mouse RAW264.7 cells to ratio of IC50 for human MCF7 cells2019European journal of medicinal chemistry, Nov-15, Volume: 182Novel 4-quinoline-thiosemicarbazone derivatives: Synthesis, antiproliferative activity, in vitro and in silico biomacromolecule interaction studies and topoisomerase inhibition.
AID1133942Lipophilic-hydrophilic balance, Rm of the compound by reversed-phase partition chromatography1977Journal of medicinal chemistry, Apr, Volume: 20, Issue:4
Potential antitumor agents. 22. Latentiated congeners of the 4'-(9-acridinylamino)methanesulfonanilides.
AID1609097Inhibition of recombinant human topoisomerase 2alpha using supercoiled pUC19 plasmid DNA as substrate at 10 uM incubated for 45 mins by ethidium bromide dye based agarose gel electrophoresis method2019European journal of medicinal chemistry, Nov-15, Volume: 182Novel 4-quinoline-thiosemicarbazone derivatives: Synthesis, antiproliferative activity, in vitro and in silico biomacromolecule interaction studies and topoisomerase inhibition.
AID199186Ability to block cleavage of G/GNCC site in Restriction endonuclease Sau961 with the test compound/DNA ratio 4(no. of sites=15); - = no activation1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Properties of the nucleic acid photoaffinity labeling agent 3-azidoamsacrine.
AID1384115Inhibition of human topoisomerase-2B after 2 hrs by ELISA2018European journal of medicinal chemistry, Apr-25, Volume: 150Novel ciprofloxacin hybrids using biology oriented drug synthesis (BIODS) approach: Anticancer activity, effects on cell cycle profile, caspase-3 mediated apoptosis, topoisomerase II inhibition, and antibacterial activity.
AID54263DNA-bound drug concentration in 0.1 SHE buffer at the concentration of 50 uM for equilibrium binding to calf thymus DNA1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Kinetic and equilibrium binding studies of amsacrine-4-carboxamides: a class of asymmetrical DNA-intercalating agents which bind by threading through the DNA helix.
AID111209In vitro anticancer activity against B6D2F-1 mice bearing P388 leukemia measured by the average weight change(g) after day 7 at an intravenous dose of 18(mg/kg).1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Synthesis and structure-activity relationships of potential anticancer agents: alkylcarbamates of 3-(9-acridinylamino)-5-hydroxymethylaniline.
AID229742Hypersensitivity factor (HF) of IC50 (AA8) / IC50 (UV-4) of compound for repair deffective mutants1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Hypoxia-selective antitumor agents. 2. Electronic effects of 4-substituents on the mechanisms of cytotoxicity and metabolic stability of nitracrine derivatives.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID363203Antitumor activity against human NCI60 cells after 48 hrs by SRB assay2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
Design, synthesis, and antitumor activity of new bis-aminomethylnaphthalenes.
AID1294870Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay2016European journal of medicinal chemistry, Jun-30, Volume: 116Synthesis and antiproliferative activity of 9-benzylamino-6-chloro-2-methoxy-acridine derivatives as potent DNA-binding ligands and topoisomerase II inhibitors.
AID232336Ratio of BR1 IC50 to xrs-6 IC501995Journal of medicinal chemistry, Oct-27, Volume: 38, Issue:22
Topoisomerase II-mediated DNA cleavage by adocia- and xestoquinones from the Philippine sponge Xestospongia sp.
AID229284Ratio of IC50 of HCT-8 to IC50 of L1210 cell lines1987Journal of medicinal chemistry, Apr, Volume: 30, Issue:4
Potential antitumor agents. 48. 3'-Dimethylamino derivatives of amsacrine: redox chemistry and in vivo solid tumor activity.
AID152553In vivo for antitumor activity against P388 leukemia1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Potential antitumor agents. 47. 3'-Methylamino analogues of amsacrine with in vivo solid tumor activity.
AID147016Ability to block cleavage of CC/CGGG site in NciI enzyme with the test compound/DNA ratio 1(no. of sites=10); - = no activation1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Properties of the nucleic acid photoaffinity labeling agent 3-azidoamsacrine.
AID35547Ability to block cleavage of AG/CT site in AluI enzyme with the test compound, DNA ratio 4(no. of sites=16); - = no activation1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Properties of the nucleic acid photoaffinity labeling agent 3-azidoamsacrine.
AID1609093Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay2019European journal of medicinal chemistry, Nov-15, Volume: 182Novel 4-quinoline-thiosemicarbazone derivatives: Synthesis, antiproliferative activity, in vitro and in silico biomacromolecule interaction studies and topoisomerase inhibition.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID426108Binding affinity to salmon testes DNA assessed as occurrence of intercalative molecular complex by linear flow dichroism2009European journal of medicinal chemistry, Jul, Volume: 44, Issue:7
DNA-targeting pyrroloquinoline-linked butenone and chalcones: synthesis and biological evaluation.
AID107799Mean value of mutation induction for L5178Y cells was evaluated at dose 0.005 mg/mL in dark condition (expt-II)1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Properties of the nucleic acid photoaffinity labeling agent 3-azidoamsacrine.
AID55657Time constant describing the dissociation profile of calf thymus DNA-drug complexes in 0.1 SHE buffer at 20 degree C1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Kinetic and equilibrium binding studies of amsacrine-4-carboxamides: a class of asymmetrical DNA-intercalating agents which bind by threading through the DNA helix.
AID108704The compound (5 mg/kg, ip) was tested for change in average weight of BDF2 mice bearing Lewis lung carcinoma1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
9-substituted acridine derivatives with long half-life and potent antitumor activity: synthesis and structure-activity relationships.
AID103477In vivo antitumor activity against Lewis lung carcinoma cells expressed as percent increase in lifespan at an optimal dose of 13.3 mg/kg/day1987Journal of medicinal chemistry, Apr, Volume: 30, Issue:4
Potential antitumor agents. 48. 3'-Dimethylamino derivatives of amsacrine: redox chemistry and in vivo solid tumor activity.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID665978Cytotoxicity against chinese hamster V79 cells after 72 hrs by MTT assay2012Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11
Synthesis and cytotoxic activity of new acridine-thiazolidine derivatives.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1695178Binding affinity to DNA isolated from human A549 cells assessed as intercalating activity at 100 uM after 1 hr by electrophoretic mobility shift assay
AID152520In vivo tumor cell selectivity (ILSmax values)for percentage increase in life span of treated animals over that of P388 tumor bearing untreated control animals1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Potential antitumor agents. 42. Structure-activity relationships for acridine-substituted dimethyl phosphoramidate derivatives of 9-anilinoacridine.
AID355584Antiproliferative activity against mouse P388 cells at 1 ug after 48 hrs by two-layer agar-diffusion method
AID103106Inhibitory activity of tested against Murine Lewis lung carcinoma1999Journal of medicinal chemistry, Jul-01, Volume: 42, Issue:13
Structure-activity relationships for substituted bis(acridine-4-carboxamides): a new class of anticancer agents.
AID317174Antiproliferative activity against human HeLa cells after 72 hrs by trypan blue test2008Bioorganic & medicinal chemistry, Mar-01, Volume: 16, Issue:5
Synthesis and biological evaluation of pyrroloiminoquinone derivatives.
AID145206Inhibitory activity against NCI-H358 cell line using MTT assay(mutant p53)2000Journal of medicinal chemistry, Apr-20, Volume: 43, Issue:8
Antitumor polycyclic acridines. 7. Synthesis and biological properties of DNA affinic tetra- and pentacyclic acridines.
AID150524In vitro cell growth inhibitory activity was determined against amsacrine-resistant P388 cell line (P388/A).1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Potential antitumor agents. 59. Structure-activity relationships for 2-phenylbenzimidazole-4-carboxamides, a new class of "minimal" DNA-intercalating agents which may not act via topoisomerase II.
AID107806Relative toxicity against mammalian L5178Y cells at dose 0.005 mg/mL in light condition (expt-II)1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Properties of the nucleic acid photoaffinity labeling agent 3-azidoamsacrine.
AID365815Cytotoxicity against human M4Beu cells by Hoechst test2008Bioorganic & medicinal chemistry, Aug-15, Volume: 16, Issue:16
Design, synthesis and preliminary biological evaluation of acridine compounds as potential agents for a combined targeted chemo-radionuclide therapy approach to melanoma.
AID355583Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay
AID139101Percent increase in life span in L1210 assay at the LD10 dose1980Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
Potential antitumor agents. 33. Quantitative structure--activity relationships for mutagenic activity and antitumor activity of substituted 4'-(9-acridinylamino)methanesulfonanilide derivatives.
AID111064In vitro anticancer activity against B6D2F-1 mice bearing P388 leukemia measured by the average weight change(g) after day 1 at an intravenous dose of 8(mg/kg).1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Synthesis and structure-activity relationships of potential anticancer agents: alkylcarbamates of 3-(9-acridinylamino)-5-hydroxymethylaniline.
AID80703Tested for the cytotoxicity to inhibit replication assay against the human colon tumor cell line HCT1161994Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22
Inhibition of topoisomerase II catalytic activity by pyridoacridine alkaloids from a Cystodytes sp. ascidian: a mechanism for the apparent intercalator-induced inhibition of topoisomerase II.
AID1382604Inhibition of ethidium bromide binding to Escherichia coli pBR322 DNA at 100 uM after 30 mins by fluorescence assay2018European journal of medicinal chemistry, Mar-25, Volume: 148Structure-based discovery of cytotoxic dimeric tetrahydroxanthones as potential topoisomerase I inhibitors from a marine-derived fungus.
AID1695172Cell cycle arrest in human A549 cells assessed as accumulation in S phase at IC50 concentration incubated for 24 hrs by RNaseA/propidium iodide staining based flow cytometry
AID119953Dose of drug given intraperitoneally on a qd 1-5 schedule that provides the highest ILS value in mice bearing 10E6 ip inoculated L1210 leukemia cells1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Potential antitumor agents. 41. Analogues of amsacrine with electron-donor substituents in the anilino ring.
AID153434In vivo antitumor activity in mice bearing P388 leukemia cells at an optimal dose of 13.3 mg/kg given on days 1,5,9.1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Potential antitumor agents. 40. Orally active 4,5-disubstituted derivatives of amsacrine.
AID1434042Poison activity at recombinant human topoisomerase-2alpha catalytic domain (431 to 1193 residues) assessed as increase in double stranded DNA cleavage at 50 uM using supercoiled pBR322 DNA as substrate measured after 6 mins by ethidium bromide staining ba2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Novel trifluoromethylated 9-amino-3,4-dihydroacridin-1(2H)-ones act as covalent poisons of human topoisomerase IIα.
AID1609094Cytotoxicity against human T47D cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay2019European journal of medicinal chemistry, Nov-15, Volume: 182Novel 4-quinoline-thiosemicarbazone derivatives: Synthesis, antiproliferative activity, in vitro and in silico biomacromolecule interaction studies and topoisomerase inhibition.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID355286DNA damaging activity against wild-type Saccharomyces cerevisiae assessed as drug level required to produce 12 mm zone of inhibition assessed per 100 uL after 48 hrs1997Journal of natural products, Oct, Volume: 60, Issue:10
Three new pseudodistomins, piperidine alkaloids from the ascidian Pseudodistoma megalarva.
AID199188Ability to block cleavage of G/GNCC site in Restriction endonuclease Sau961 with the test compound/DNA ratio 1:8(no. of sites=15); - = no activation1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Properties of the nucleic acid photoaffinity labeling agent 3-azidoamsacrine.
AID111073In vitro anticancer activity against B6D2F-1 mice bearing P388 leukemia measured by the average weight change(g) after day 11 at an intravenous dose of 8(mg/kg).1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Synthesis and structure-activity relationships of potential anticancer agents: alkylcarbamates of 3-(9-acridinylamino)-5-hydroxymethylaniline.
AID19531Half-life was evaluated in water in the presence of light1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Properties of the nucleic acid photoaffinity labeling agent 3-azidoamsacrine.
AID55304Inhibitory concentration against DNA-bound ethidium for cytotoxicity1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Novel acridine-triazenes as prototype combilexins: synthesis, DNA binding, and biological activity.
AID386536Inhibition of human ERG potassium channel2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
A binary QSAR model for classification of hERG potassium channel blockers.
AID229743Hypersensitivity factor (HF) of IC50 (AA8) / IC50 (UV-5) of compound for repair deffective mutants1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Hypoxia-selective antitumor agents. 2. Electronic effects of 4-substituents on the mechanisms of cytotoxicity and metabolic stability of nitracrine derivatives.
AID1811236Inhibition of human topoisomerase I using DNA pBR322 as substrate assessed as DNA intercalation at 100 uM incubated for 30 mins by ethidium bromide staining based agarose gel electrophoresis method2021European journal of medicinal chemistry, Dec-15, Volume: 226N-2-(phenylamino) benzamide derivatives as novel anti-glioblastoma agents: Synthesis and biological evaluation.
AID1145943Cytotoxicity against mouse L1210 cells assessed as growth inhibition at 1 ug/ml after 48 hrs1976Journal of medicinal chemistry, Aug, Volume: 19, Issue:8
Synthesis and biological properties of some spin-labeled 9-aminoacridines.
AID227751Concentration required to reduce ethidium bromide fluorescence to 50% of control in presence of calf thymus DNA; ND is Not Determined.1994Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22
Inhibition of topoisomerase II catalytic activity by pyridoacridine alkaloids from a Cystodytes sp. ascidian: a mechanism for the apparent intercalator-induced inhibition of topoisomerase II.
AID312292Cytotoxicity against human K562 cells after 5 days by XTT assay2007Journal of natural products, Dec, Volume: 70, Issue:12
Curcumin induces high levels of topoisomerase I- and II-DNA complexes in K562 leukemia cells.
AID320271Antiproliferative activity against human K562 cells after 72 hrs by MTT assay2008Bioorganic & medicinal chemistry, Feb-01, Volume: 16, Issue:3
Synthesis, cytotoxic evaluation, and DNA binding of novel thiazolo[5,4-b]quinoline derivatives.
AID98819Drug concentration in mole/kg/day providing 50% extension of life in intraperitoneally implanted leukemia L1210 mice.1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Potential antitumor agents. 36. Quantitative relationships between experimental antitumor activity, toxicity, and structure for the general class of 9-anilinoacridine antitumor agents.
AID111075In vitro anticancer activity against B6D2F-1 mice bearing P388 leukemia measured by the average weight change(g) after day 7 at an intravenous dose of 12(mg/kg).1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Synthesis and structure-activity relationships of potential anticancer agents: alkylcarbamates of 3-(9-acridinylamino)-5-hydroxymethylaniline.
AID25369Compound was evaluated for the protonation constant by binding to DNA by intercalation in calf thymus.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
A new ionizable chromophore of 1,4-bis(alkylamino)benzo[g]phthalazine which interacts with DNA by intercalation.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID355581Antiproliferative activity against human HT-29 cells at 0.1 ug after 48 hrs by two-layer agar-diffusion method
AID1478730Displacement of ethidium bromide from calf thymus DNA up to 40 uM after 30 mins by fluorescence assay2017European journal of medicinal chemistry, Jun-16, Volume: 133Dihydroxylated 2,6-diphenyl-4-chlorophenylpyridines: Topoisomerase I and IIα dual inhibitors with DNA non-intercalative catalytic activity.
AID456324Growth inhibition of human NCI60 cells2010Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1
Synthesis and antiproliferative evaluations of certain 2-phenylvinylquinoline (2-styrylquinoline) and 2-furanylvinylquinoline derivatives.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID671590Inhibition of human recombinant topoisomerase 2alpha-mediated pBR322 DNA complex formation at 8 uM after 60 mins by agarose gel electrophoresis2012Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11
A novel tetrahydrobenzoangelicin with dark and photo biological activity.
AID538150Binding affinity to calf thymus DNA assessed as ratio of final absorbance area to absorbance of compound at 100 uM after 24 hrs by UV spectrophotometer analysis2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Structural modifications on the phenazine N,N'-dioxide-scaffold looking for new selective hypoxic cytotoxins.
AID665981Antiproliferative activity against human UACC62 cells after 72 hrs by MTT assay2012Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11
Synthesis and cytotoxic activity of new acridine-thiazolidine derivatives.
AID1145947Cytotoxicity against mouse L1210 cells assessed as growth inhibition at 0.01 ug/ml after 48 hrs1976Journal of medicinal chemistry, Aug, Volume: 19, Issue:8
Synthesis and biological properties of some spin-labeled 9-aminoacridines.
AID1655302Growth inhibition of human HeLa cells incubated for 72 hrs by trypan blue assay2020ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5
Synthesis, Antiproliferative Effect, and Topoisomerase II Inhibitory Activity of 3-Methyl-2-phenyl-1
AID1396989Antiproliferative activity against human U937 cells after 48 hrs by MTT assay2018Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14
Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors.
AID1149744Retardation factor, Rm of the compound by reversed phase partition chromatography1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Potential antitumor agents. 23. 4'-(9-Acridinylamino)alkanesulfonanilide congeners bearing hydrophilic functionality.
AID665977Cytotoxicity against human PBMC after 72 hrs by alamar blue assay2012Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11
Synthesis and cytotoxic activity of new acridine-thiazolidine derivatives.
AID226889Ratio of inhibitory concentration of Human Jurkat leukemia D (JLD) and Human Jurkat leukemia C (JLC)1997Journal of medicinal chemistry, Jun-20, Volume: 40, Issue:13
Synthesis and antitumor properties of N-[2-(dimethylamino)ethyl]carboxamide derivatives of fused tetracyclic quinolines and quinoxalines: a new class of putative topoisomerase inhibitors.
AID114262In vivo antitumor activity against subcutaneous Colon 38 tumors in mice determined as delay in growth after 13.3 mg/kg/day dose given as 3 times in a day for 4 days2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Synthesis and cytotoxic activity of carboxamide derivatives of benzo[b][1,6]naphthyridines.
AID1631067Inhibition of human recombinant topoisomerase-2 alpha expressed in Escherichia coli assessed as reduction in supercoiled pBR322 DNA relaxation at 8 uM after 60 mins by ethidium bromide staining based agarose gel electrophoresis2016Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20
Novel benzoquinoline derivatives via unpredicted condensation of ethyl propiolate and naphthylamines: Synthesis and topoisomerase inhibition activity.
AID665982Antiproliferative activity against human DU145 cells after 72 hrs by MTT assay2012Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11
Synthesis and cytotoxic activity of new acridine-thiazolidine derivatives.
AID302338Inhibition of human recombinant topoisomerase 2-mediated relaxation of supercoiled plasmid pBR322 DNA at 8 uM2007Bioorganic & medicinal chemistry letters, Nov-15, Volume: 17, Issue:22
3,5-bis(3'-indolyl)pyrazoles, analogues of marine alkaloid nortopsentin: synthesis and antitumor properties.
AID678714Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID227079Ratio of IC50 against Jurkat human leukemia doxorubicin-resistant cells (JLD) to Jurkat human leukemia cells (JLC)2001Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12
Synthesis and cytotoxic activity of 7-oxo-7H-dibenz[f,ij]isoquinoline and 7-oxo-7H-benzo[e]perimidine derivatives.
AID43704Cytotoxicity in human leukemic CCRF-CEM cells.2003Journal of medicinal chemistry, Dec-18, Volume: 46, Issue:26
Bisintercalating threading diacridines: relationships between DNA binding, cytotoxicity, and cell cycle arrest.
AID547841Inhibition of guinea pig aldehyde oxidase2010Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24
Aldehyde oxidase: an enzyme of emerging importance in drug discovery.
AID351112Cytotoxicity against human SW620 cells after 72 hrs by MTT assay2009Bioorganic & medicinal chemistry, May-01, Volume: 17, Issue:9
Synthesis, cytotoxic activity, DNA topoisomerase-II inhibition, molecular modeling and structure-activity relationship of 9-anilinothiazolo[5,4-b]quinoline derivatives.
AID1610468Antiproliferative against human U937 cells incubated for 72 hrs by MTT assay2019Bioorganic & medicinal chemistry letters, 12-01, Volume: 29, Issue:23
Design, synthesis and biological research of novel N-phenylbenzamide-4-methylamine acridine derivatives as potential topoisomerase I/II and apoptosis-inducing agents.
AID1145942Cytotoxicity against mouse L1210 cells assessed as growth inhibition at 1 ug/ml after 24 hrs1976Journal of medicinal chemistry, Aug, Volume: 19, Issue:8
Synthesis and biological properties of some spin-labeled 9-aminoacridines.
AID576612Inhibition of human ERG2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
AID427938Stabilization of supercoiled pBR322 DNA-human recombinant topoisomerase 2 complex assessed as reduction in linear DNA formation at 8 uM2009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
Benzothiopyranoindole-based antiproliferative agents: synthesis, cytotoxicity, nucleic acids interaction, and topoisomerases inhibition properties.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID55134Binding constant for DNA by ethidium bromide displacement1987Journal of medicinal chemistry, Sep, Volume: 30, Issue:9
Potential antitumor agents. 52. Carbamate analogues of amsacrine with in vivo activity against multidrug-resistant P388 leukemia.
AID146876Ability to block cleavage of GCC/GGC site in NaeI enzyme with the test compound/DNA ratio 1(no. of sites=4); - = no activation1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Properties of the nucleic acid photoaffinity labeling agent 3-azidoamsacrine.
AID355582Antiproliferative activity against human HT-29 cells at 0.01 ug after 48 hrs by two-layer agar-diffusion method
AID123409In vitro anticancer activity against 5 B6D2F-1 mice bearing P388 leukemia measured by the toxicity death at an intravenous dose of 18(mg/kg).1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Synthesis and structure-activity relationships of potential anticancer agents: alkylcarbamates of 3-(9-acridinylamino)-5-hydroxymethylaniline.
AID1328420Inhibition of DltB in Taro deficient Staphylococcus aureus Newman at 5 ug/ml after 16 to 18 hrs2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Accelerating the discovery of antibacterial compounds using pathway-directed whole cell screening.
AID1695168Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
AID1453388Antiproliferative activity against human QSG7701 cells after 48 hrs by MTT assay2017Bioorganic & medicinal chemistry, 07-01, Volume: 25, Issue:13
Synthesis and biological research of novel azaacridine derivatives as potent DNA-binding ligands and topoisomerase II inhibitors.
AID20508Chromatographic measure of drug lipophilicity1983Journal of medicinal chemistry, Nov, Volume: 26, Issue:11
Potential antitumor agents. 39. Anilino ring geometry of amsacrine and derivatives: relationship to DNA binding and antitumor activity.
AID347898Binding affinity to salmon testes DNA assessed as negative dichroic signal by linear dichroism experiment2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Synthesis and antitumor activity of novel amsacrine analogs: the critical role of the acridine moiety in determining their biological activity.
AID307100Cytotoxicity against human MDA-MB468 cells by XTT assay2007Bioorganic & medicinal chemistry letters, May-15, Volume: 17, Issue:10
Analogs of the marine alkaloid makaluvamines: synthesis, topoisomerase II inhibition, and anticancer activity.
AID1328417Inhibition of DltB F255L mutant in Staphylococcus aureus Newman up to 32 ug/ml after 16 to 18 hrs by spectrophotometric analysis2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Accelerating the discovery of antibacterial compounds using pathway-directed whole cell screening.
AID19530Half-life was evaluated in water in the absence of light1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Properties of the nucleic acid photoaffinity labeling agent 3-azidoamsacrine.
AID1695171Cell cycle arrest in human A549 cells assessed as accumulation in SubG1 phase by measuring late apoptotic cells with fragmented DNA content at IC50 concentration incubated for 48 hrs by RNaseA/propidium iodide staining based flow cytometry
AID351111Cytotoxicity against human SW480 cells after 72 hrs by MTT assay2009Bioorganic & medicinal chemistry, May-01, Volume: 17, Issue:9
Synthesis, cytotoxic activity, DNA topoisomerase-II inhibition, molecular modeling and structure-activity relationship of 9-anilinothiazolo[5,4-b]quinoline derivatives.
AID54240Fraction of the observed equilibrium absorbance change accounted in the kinetic analysis.1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Kinetic and equilibrium binding studies of amsacrine-4-carboxamides: a class of asymmetrical DNA-intercalating agents which bind by threading through the DNA helix.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1401822Poison activity at human topoisomerase 1 assessed as induction of relaxation of pHOT1 DNA substrate at 100 to 1000 uM incubated for 30 mins by ethidium bromide dye-based agarose gel electrophoresis analysis2018European journal of medicinal chemistry, Jan-01, Volume: 143Design, synthesis, and biological evaluation of 1,3-diarylisoquinolines as novel topoisomerase I catalytic inhibitors.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID355578Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay
AID47003The compound was tested for the cytotoxicity against human leukemic CEM/VBL cell lines1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
9-substituted acridine derivatives with long half-life and potent antitumor activity: synthesis and structure-activity relationships.
AID665991Antiproliferative activity against human CEM cells after 72 hrs by MTT assay2012Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11
Synthesis and cytotoxic activity of new acridine-thiazolidine derivatives.
AID1453387Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay2017Bioorganic & medicinal chemistry, 07-01, Volume: 25, Issue:13
Synthesis and biological research of novel azaacridine derivatives as potent DNA-binding ligands and topoisomerase II inhibitors.
AID143360Inhibitory activity against NCI-H647 cell line using MTT assay(mutant p53)2000Journal of medicinal chemistry, Apr-20, Volume: 43, Issue:8
Antitumor polycyclic acridines. 7. Synthesis and biological properties of DNA affinic tetra- and pentacyclic acridines.
AID671588Inhibition of human recombinant topoisomerase 2alpha-mediated pBR322 DNA relaxation at 8 uM after 60 mins by agarose gel electrophoretic analysis2012Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11
A novel tetrahydrobenzoangelicin with dark and photo biological activity.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID88457Ability to block cleavage of G/ANTC site in Hinf1 enzyme with the test compound/DNA ratio 1(no. of sites=10); - = no activation1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Properties of the nucleic acid photoaffinity labeling agent 3-azidoamsacrine.
AID81631In vitro cytotoxicity against human leukemic HL-60 cell line.1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
9-substituted acridine derivatives with long half-life and potent antitumor activity: synthesis and structure-activity relationships.
AID497321Stabilization of supercoiled pBR322 DNA-human recombinant topoisomerase 2 complex assessed as linear DNA formation at 8 uM after 60 mins2010Bioorganic & medicinal chemistry, Aug-01, Volume: 18, Issue:15
Pyridazinopsoralens of wide chemotherapeutic interest.
AID20511Lipophilicity (Rm) (liquid chromatography)1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Potential antitumor agents. 42. Structure-activity relationships for acridine-substituted dimethyl phosphoramidate derivatives of 9-anilinoacridine.
AID96799In vitro concentration required to reduce the murine L1210 leukemia cells in cultures to 50% after a period of 72 hr.1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Potential antitumor agents. 40. Orally active 4,5-disubstituted derivatives of amsacrine.
AID150213In vivo activity against P388 leukemia cells1987Journal of medicinal chemistry, Apr, Volume: 30, Issue:4
Potential antitumor agents. 48. 3'-Dimethylamino derivatives of amsacrine: redox chemistry and in vivo solid tumor activity.
AID657773Cytocidal activity against human M21 cells assessed as growth inhibition after 48 hrs by SRB assay2012European journal of medicinal chemistry, Jun, Volume: 52Imidazonaphthyridine systems (part 2): Functionalization of the phenyl ring linked to the pyridine pharmacophore and its replacement by a pyridinone ring produces intriguing differences in cytocidal activity.
AID108702The compound (5 mg/kg, ip) was tested for change in average weight of BDF2 mice bearing B-16 melanoma1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
9-substituted acridine derivatives with long half-life and potent antitumor activity: synthesis and structure-activity relationships.
AID317175Antiproliferative activity against human HL60 cells after 72 hrs by trypan blue test2008Bioorganic & medicinal chemistry, Mar-01, Volume: 16, Issue:5
Synthesis and biological evaluation of pyrroloiminoquinone derivatives.
AID96632In vitro test for 50% reduction of cell number (of control) after 70 hr incubation with cultures of murine L1210 leukemia cells1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Potential antitumor agents. 42. Structure-activity relationships for acridine-substituted dimethyl phosphoramidate derivatives of 9-anilinoacridine.
AID1145938Cytotoxicity against mouse L1210 cells assessed as growth inhibition at 100 ug/ml after 24 hrs1976Journal of medicinal chemistry, Aug, Volume: 19, Issue:8
Synthesis and biological properties of some spin-labeled 9-aminoacridines.
AID150694Concentration for inhibiting the growth of P-388 cells by 50% over 3 days was determined1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Potential antitumor agents. 37. Organophosphorus derivatives of 9-anilinoacridine.
AID680267TP_TRANSPORTER: increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.5 uM, m-Amsacrine: 5 uM) in MDR1-expressing NIH-3T3 cells2004Biochemical and biophysical research communications, Mar-19, Volume: 315, Issue:4
Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies.
AID232294Differential cytotoxicity was determined from the ratio between BR1(IC50) and xrs-6 (IC50)1994Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22
Inhibition of topoisomerase II catalytic activity by pyridoacridine alkaloids from a Cystodytes sp. ascidian: a mechanism for the apparent intercalator-induced inhibition of topoisomerase II.
AID54264Free drug concentration in 0.1 SHE buffer at the concentration of 50 uM for equilibrium binding to calf thymus DNA1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Kinetic and equilibrium binding studies of amsacrine-4-carboxamides: a class of asymmetrical DNA-intercalating agents which bind by threading through the DNA helix.
AID135921compound was tested for murine tumor growth inhibition,T/C value (total/control) in mice.1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
Synthesis and antitumor activity of 4-aminomethylthioxanthenone and 5-aminomethylbenzothiopyranoindazole derivatives.
AID678713Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID101620Inhibitory activity against MDA-468 cell line using MTT assay (ER-, amplified EGFR, mutant p53)2000Journal of medicinal chemistry, Apr-20, Volume: 43, Issue:8
Antitumor polycyclic acridines. 7. Synthesis and biological properties of DNA affinic tetra- and pentacyclic acridines.
AID1655303Growth inhibition of human A2780 cells incubated for 72 hrs by trypan blue assay2020ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5
Synthesis, Antiproliferative Effect, and Topoisomerase II Inhibitory Activity of 3-Methyl-2-phenyl-1
AID1148472Induction of bacteriophage PM2 closed circular DNA unwinding assessed as drug per nucleic acid phosphate ratio at equivalence by viscometric analysis1978Journal of medicinal chemistry, Jul, Volume: 21, Issue:7
Potenial antitumor agents. 28. Deoxyribonucleic acid polyintercalating agents.
AID120027Average tumor volume of the Lewis lung carcinoma1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
9-substituted acridine derivatives with long half-life and potent antitumor activity: synthesis and structure-activity relationships.
AID201226The mutagenic effectiveness, lowest molar concentration required for a constant proportion of revertant colonies (chosen as 50 per 10E8 bacteria)1980Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
Potential antitumor agents. 33. Quantitative structure--activity relationships for mutagenic activity and antitumor activity of substituted 4'-(9-acridinylamino)methanesulfonanilide derivatives.
AID65959Ability to block cleavage of TTT/AAA site in DraI enzyme with the test compound/DNA ratio 1(no. of sites=3); - = no activation1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Properties of the nucleic acid photoaffinity labeling agent 3-azidoamsacrine.
AID111215In vitro anticancer activity against B6D2F-1 mice bearing P388 leukemia measured by the average weight change(g) after day 7 at an intravenous dose of 8(mg/kg).1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Synthesis and structure-activity relationships of potential anticancer agents: alkylcarbamates of 3-(9-acridinylamino)-5-hydroxymethylaniline.
AID153877Percentage increase in life span was measured for P-388 cells in culture after intraperitoneal administration of a dose of 13.3 mg/kg1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Potential antitumor agents. 37. Organophosphorus derivatives of 9-anilinoacridine.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID211312Percent of DNA remaining uncut after incubation with Topoisomerase II at 10 uM concentration1998Bioorganic & medicinal chemistry letters, Jan-20, Volume: 8, Issue:2
Synthesis, DNA-damaging and cytotoxic properties of novel topoisomerase II-directed bisantrene analogues.
AID225777Inhibitory concentration against ethidium in DNA-binding assay with [poly(dA-dT)]2 (synthetic oligonucleotide)1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Novel acridine-triazenes as prototype combilexins: synthesis, DNA binding, and biological activity.
AID383234Cell cycle arrest in human OVCAR-3 cells assessed as accumulation at S phase at 16 uM by flow cytometry2008European journal of medicinal chemistry, Feb, Volume: 43, Issue:2
Discovery of a new anilino-3H-pyrrolo[3,2-f]quinoline derivative as potential anti-cancer agent.
AID1294869Antiproliferative activity against human A549 cells after 48 hrs by MTT assay2016European journal of medicinal chemistry, Jun-30, Volume: 116Synthesis and antiproliferative activity of 9-benzylamino-6-chloro-2-methoxy-acridine derivatives as potent DNA-binding ligands and topoisomerase II inhibitors.
AID25641Half life of the drug was determined in the presence of 2-mercaptoethanol1983Journal of medicinal chemistry, Nov, Volume: 26, Issue:11
Potential antitumor agents. 39. Anilino ring geometry of amsacrine and derivatives: relationship to DNA binding and antitumor activity.
AID320268Antiproliferative activity against human C33 cells after 72 hrs by MTT assay2008Bioorganic & medicinal chemistry, Feb-01, Volume: 16, Issue:3
Synthesis, cytotoxic evaluation, and DNA binding of novel thiazolo[5,4-b]quinoline derivatives.
AID211310Percent of DNA remaining uncut after incubation with Topoisomerase II at 0.1 uM concentration1998Bioorganic & medicinal chemistry letters, Jan-20, Volume: 8, Issue:2
Synthesis, DNA-damaging and cytotoxic properties of novel topoisomerase II-directed bisantrene analogues.
AID88459Ability to block cleavage of G/ANTC site in Hinf1 enzyme with the test compound/DNA ratio 4(no. of sites=10); - = no activation1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Properties of the nucleic acid photoaffinity labeling agent 3-azidoamsacrine.
AID220406Inhibitory activity against ZR-75-1 cell line using MTT assay (ER+,pgr+,mutant p53)2000Journal of medicinal chemistry, Apr-20, Volume: 43, Issue:8
Antitumor polycyclic acridines. 7. Synthesis and biological properties of DNA affinic tetra- and pentacyclic acridines.
AID774945Induction of pHOT1 DNA (unknown origin) intercalating activity assessed as blockade of DNA unwinding at 50 to 500 uM after 30 mins by agarose gel electrophoresis in presence of DNA topoisomerase-12013European journal of medicinal chemistry, Nov, Volume: 693-(3-Butylamino-2-hydroxy-propoxy)-1-hydroxy-xanthen-9-one acts as a topoisomerase IIα catalytic inhibitor with low DNA damage.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID199185Ability to block cleavage of G/GNCC site in Restriction endonuclease Sau961 with the test compound/DNA ratio 1:8(no. of sites=15); - = no activation1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Properties of the nucleic acid photoaffinity labeling agent 3-azidoamsacrine.
AID96055Activity of the topoisomerase II dependent DNA cleavage; Active1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
Synthesis and antitumor activity of fused tetracyclic quinoline derivatives. 1.
AID1145941Cytotoxicity against mouse L1210 cells assessed as growth inhibition at 10 ug/ml after 48 hrs1976Journal of medicinal chemistry, Aug, Volume: 19, Issue:8
Synthesis and biological properties of some spin-labeled 9-aminoacridines.
AID383233Cell cycle arrest in human OVCAR-3 cells assessed as accumulation at G0/G1 phase at 16 uM by flow cytometry2008European journal of medicinal chemistry, Feb, Volume: 43, Issue:2
Discovery of a new anilino-3H-pyrrolo[3,2-f]quinoline derivative as potential anti-cancer agent.
AID91018Ability to block cleavage of C/CGG site in HpaII enzyme with the test compound/DNA ratio 1:8(no. of sites=26); - = no activation1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Properties of the nucleic acid photoaffinity labeling agent 3-azidoamsacrine.
AID91019Ability to block cleavage of C/CGG site in HpaII enzyme with the test compound/DNA ratio 4(no. of sites=26); - = no activation1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Properties of the nucleic acid photoaffinity labeling agent 3-azidoamsacrine.
AID54960Percentage of the sum of the amplitudes in the kinetic experiment.1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Kinetic and equilibrium binding studies of amsacrine-4-carboxamides: a class of asymmetrical DNA-intercalating agents which bind by threading through the DNA helix.
AID107805Relative toxicity against mammalian L5178Y cells at dose 0.005 mg/mL in dark condition (expt-II)1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Properties of the nucleic acid photoaffinity labeling agent 3-azidoamsacrine.
AID320267Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay2008Bioorganic & medicinal chemistry, Feb-01, Volume: 16, Issue:3
Synthesis, cytotoxic evaluation, and DNA binding of novel thiazolo[5,4-b]quinoline derivatives.
AID219914Cytotoxicity against CHO cell line xrs61995Journal of medicinal chemistry, Oct-27, Volume: 38, Issue:22
Topoisomerase II-mediated DNA cleavage by adocia- and xestoquinones from the Philippine sponge Xestospongia sp.
AID134224In vivo toxicity (qd 1-5), determined using the intraperitoneal implantation of L1210 leukemia cells in mice1980Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
Potential antitumor agents. 33. Quantitative structure--activity relationships for mutagenic activity and antitumor activity of substituted 4'-(9-acridinylamino)methanesulfonanilide derivatives.
AID227078Ratio of IC50 against Jurkat human leukemia amsacrine-resistant cells (JLA) to Jurkat human leukemia cells (JLC)2001Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12
Synthesis and cytotoxic activity of 7-oxo-7H-dibenz[f,ij]isoquinoline and 7-oxo-7H-benzo[e]perimidine derivatives.
AID1328414Inhibition of DltB tn::1050 mutant in Staphylococcus aureus Newman up to 32 ug/ml after 16 to 18 hrs by spectrophotometric analysis2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Accelerating the discovery of antibacterial compounds using pathway-directed whole cell screening.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1145940Cytotoxicity against mouse L1210 cells assessed as growth inhibition at 10 ug/ml after 24 hrs1976Journal of medicinal chemistry, Aug, Volume: 19, Issue:8
Synthesis and biological properties of some spin-labeled 9-aminoacridines.
AID111065In vitro anticancer activity against B6D2F-1 mice bearing P388 leukemia measured by the average weight change(g) after day 11 at an intravenous dose of 12(mg/kg).1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Synthesis and structure-activity relationships of potential anticancer agents: alkylcarbamates of 3-(9-acridinylamino)-5-hydroxymethylaniline.
AID1610467Antiproliferative against human K562 cells incubated for 72 hrs by MTT assay2019Bioorganic & medicinal chemistry letters, 12-01, Volume: 29, Issue:23
Design, synthesis and biological research of novel N-phenylbenzamide-4-methylamine acridine derivatives as potential topoisomerase I/II and apoptosis-inducing agents.
AID55122Binding constant (log K) for DNA by ethidium bromide displacement1987Journal of medicinal chemistry, Apr, Volume: 30, Issue:4
Potential antitumor agents. 48. 3'-Dimethylamino derivatives of amsacrine: redox chemistry and in vivo solid tumor activity.
AID1337482Poison activity at human DNA topoisomerase-1 assessed as DNA intercalation by measuring DNA unwinding using pHOT1 DNA as substrate after 30 mins by ethidium bromide staining based agarose gel electrophoresis2017European journal of medicinal chemistry, Jan-05, Volume: 125Novel 2-aryl-4-(4'-hydroxyphenyl)-5H-indeno[1,2-b]pyridines as potent DNA non-intercalative topoisomerase catalytic inhibitors.
AID150215In vivo dose of drug needed for a percentage increase of 50% in life span of tumor-bearing mice compared to untreated controls after inoculation of 10e6 P388 leukemia cells1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Potential antitumor agents. 42. Structure-activity relationships for acridine-substituted dimethyl phosphoramidate derivatives of 9-anilinoacridine.
AID150540In vitro cytotoxicity measured by quantifying clonogenic survival in soft agar following a 1-hour transient exposure of p388 mouse leukemia cells.1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
Synthesis and antitumor activity of 4-aminomethylthioxanthenone and 5-aminomethylbenzothiopyranoindazole derivatives.
AID1396988Inhibition of human topoisomerase 2alpha expressed in Escherichia coli assessed as reduction in supercoiled pBR322 plasmid DNA relaxation at 50 to 100 uM after 10 to 15 mins by ethidium bromide staining based agarose gel electrophoresis2018Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14
Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors.
AID65961Ability to block cleavage of TTT/AAA site in DraI enzyme with the test compound/DNA ratio 4(no. of sites=3); - = no activation1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Properties of the nucleic acid photoaffinity labeling agent 3-azidoamsacrine.
AID1695167Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
AID150670Inhibitory concentration to reduce cell number to 50% of Murine P388 leukemia cell culture1997Journal of medicinal chemistry, Jun-20, Volume: 40, Issue:13
Synthesis and antitumor properties of N-[2-(dimethylamino)ethyl]carboxamide derivatives of fused tetracyclic quinolines and quinoxalines: a new class of putative topoisomerase inhibitors.
AID1453395Inhibition of human topoisomerase-2 at 50 uM using supercoiled pBR322 DNA as substrate after 10 to 15 mins by ethidium bromide staining based electrophoresis relative to control2017Bioorganic & medicinal chemistry, 07-01, Volume: 25, Issue:13
Synthesis and biological research of novel azaacridine derivatives as potent DNA-binding ligands and topoisomerase II inhibitors.
AID107801Mutation frequency for L5178Y cells was evaluated at dose 0.005 mg/mL in dark condition (expt-II)1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Properties of the nucleic acid photoaffinity labeling agent 3-azidoamsacrine.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID351110Cytotoxicity against human HeLa cells after 72 hrs by MTT assay2009Bioorganic & medicinal chemistry, May-01, Volume: 17, Issue:9
Synthesis, cytotoxic activity, DNA topoisomerase-II inhibition, molecular modeling and structure-activity relationship of 9-anilinothiazolo[5,4-b]quinoline derivatives.
AID91915Inhibitory activity against Jurkat human leukemia cells2001Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12
Synthesis and cytotoxic activity of 7-oxo-7H-dibenz[f,ij]isoquinoline and 7-oxo-7H-benzo[e]perimidine derivatives.
AID107798Induction frequency for L5178Y cells was evaluated at dose 0.005 mg/mL in light condition (expt-II)1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Properties of the nucleic acid photoaffinity labeling agent 3-azidoamsacrine.
AID26528Binding affinity towards poly[d(A-T)] (fluorometric method)1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Potential antitumor agents. 42. Structure-activity relationships for acridine-substituted dimethyl phosphoramidate derivatives of 9-anilinoacridine.
AID229325Ratio of IC50 of mutant Jurkat leukemia (JLD) to the IC50 of Jurkat leukemia (JLC sensitive, wild type)1997Journal of medicinal chemistry, Jun-06, Volume: 40, Issue:12
Structure-activity relationships for acridine-substituted analogues of the mixed topoisomerase I/II inhibitor N-[2-(dimethylamino)ethyl]acridine-4-carboxamide.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID143042Inhibitory activity against NCI-H460 cell line using MTT assay2000Journal of medicinal chemistry, Apr-20, Volume: 43, Issue:8
Antitumor polycyclic acridines. 7. Synthesis and biological properties of DNA affinic tetra- and pentacyclic acridines.
AID152668In vivo inhibition of P388 in mice for optimal (highest nonacutely toxic) dose (OD)1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Potential antitumor agents. 42. Structure-activity relationships for acridine-substituted dimethyl phosphoramidate derivatives of 9-anilinoacridine.
AID1148471Displacement of ethidium bromide from calf thymus DNA by spectrofluorometric analysis1978Journal of medicinal chemistry, Jul, Volume: 21, Issue:7
Potenial antitumor agents. 28. Deoxyribonucleic acid polyintercalating agents.
AID54990Change in DNA-melting (deltaTm) with calf thymus DNA at pH 7.01995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Novel acridine-triazenes as prototype combilexins: synthesis, DNA binding, and biological activity.
AID110725In vitro anticancer activity against B6D2F-1 mice bearing P388 leukemia measured by the Average survival time(day+/-SD) at an intravenous dose of 12(mg/kg).1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Synthesis and structure-activity relationships of potential anticancer agents: alkylcarbamates of 3-(9-acridinylamino)-5-hydroxymethylaniline.
AID1294873Antiproliferative activity against human CCRF-CEM cells after 48 hrs by MTT assay2016European journal of medicinal chemistry, Jun-30, Volume: 116Synthesis and antiproliferative activity of 9-benzylamino-6-chloro-2-methoxy-acridine derivatives as potent DNA-binding ligands and topoisomerase II inhibitors.
AID107800Mean value of mutation induction for L5178Y cells was evaluated at dose 0.005 mg/mL in light condition (expt-II)1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Properties of the nucleic acid photoaffinity labeling agent 3-azidoamsacrine.
AID1352100Inhibition of ethidium bromide binding to Escherichia coli pBR322 DNA up to 100 uM by fluorescence assay2018European journal of medicinal chemistry, Feb-10, Volume: 145Synthesis of carbazole derivatives containing chalcone analogs as non-intercalative topoisomerase II catalytic inhibitors and apoptosis inducers.
AID307099Cytotoxicity against human MCF7 cells by XTT assay2007Bioorganic & medicinal chemistry letters, May-15, Volume: 17, Issue:10
Analogs of the marine alkaloid makaluvamines: synthesis, topoisomerase II inhibition, and anticancer activity.
AID1631069Poison activity at human recombinant topoisomerase-2 alpha expressed in Escherichia coli assessed as generation of linear DNA using supercoiled pBR322 DNA at 8 uM after 60 mins by ethidium bromide staining based agarose gel electrophoresis2016Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20
Novel benzoquinoline derivatives via unpredicted condensation of ethyl propiolate and naphthylamines: Synthesis and topoisomerase inhibition activity.
AID1500673Antiproliferative activity against human HCC1937 cells harboring BRCA1 mutant after 72 hrs by MTT assay2017European journal of medicinal chemistry, Sep-29, Volume: 138Design, synthesis and biological evaluation of 4-amidobenzimidazole acridine derivatives as dual PARP and Topo inhibitors for cancer therapy.
AID107802Mutation frequency for L5178Y cells was evaluated at dose 0.005 mg/mL in light condition (expt-II)1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Properties of the nucleic acid photoaffinity labeling agent 3-azidoamsacrine.
AID111055In vitro anticancer activity against B6D2F-1 mice bearing P388 leukemia measured by the average weight change(g) after day 1 at an intravenous dose of 12(mg/kg).1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Synthesis and structure-activity relationships of potential anticancer agents: alkylcarbamates of 3-(9-acridinylamino)-5-hydroxymethylaniline.
AID1148475Toxicity in ip dosed BDF1 mouse allografted with mouse P388 cells administered qd for 5 days1978Journal of medicinal chemistry, Jul, Volume: 21, Issue:7
Potenial antitumor agents. 28. Deoxyribonucleic acid polyintercalating agents.
AID1404828Inhibition of recombinant human topoisomerase 2 assessed as reduction in relaxation of supercoiled pBS-SK(+) DNA at 10 uM after 30 mins by agarose gel electrophoresis2018European journal of medicinal chemistry, Jul-15, Volume: 155Design, synthesis, molecular modeling and anti-proliferative evaluation of novel quinoxaline derivatives as potential DNA intercalators and topoisomerase II inhibitors.
AID351113Cytotoxicity against human K562 cells after 72 hrs by MTT assay2009Bioorganic & medicinal chemistry, May-01, Volume: 17, Issue:9
Synthesis, cytotoxic activity, DNA topoisomerase-II inhibition, molecular modeling and structure-activity relationship of 9-anilinothiazolo[5,4-b]quinoline derivatives.
AID154021In vivo antitumor activity against P388 cells expressed as percent increase in lifespan at an optimal dose of 13.3 mg/kg/day ip1987Journal of medicinal chemistry, Apr, Volume: 30, Issue:4
Potential antitumor agents. 48. 3'-Dimethylamino derivatives of amsacrine: redox chemistry and in vivo solid tumor activity.
AID225937Log K value for DNA binding to poly[d(A-T)]1983Journal of medicinal chemistry, Nov, Volume: 26, Issue:11
Potential antitumor agents. 38. 3-substituted 5-carboxamido derivatives of amsacrine.
AID110795Number of mice(with Colon 38 tumors) cured after treatment of 13.3 mg/kg/day dose given as 3 times in a day for 4 days out of 5 mice2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Synthesis and cytotoxic activity of carboxamide derivatives of benzo[b][1,6]naphthyridines.
AID116327In vitro anticancer activity against B6D2F-1 mice bearing P388 leukemia measured by the increase in lifespan(%) at an intravenous dose of 12(mg/kg).1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Synthesis and structure-activity relationships of potential anticancer agents: alkylcarbamates of 3-(9-acridinylamino)-5-hydroxymethylaniline.
AID111378In vitro anticancer activity against B6D2F-1 mice bearing P388 leukemia measured by the average weight change(g) after day 1 at an intravenous dose of 18(mg/kg).1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Synthesis and structure-activity relationships of potential anticancer agents: alkylcarbamates of 3-(9-acridinylamino)-5-hydroxymethylaniline.
AID95291Concentration required to inhibit 50% growth of human Jurkat cells1999Journal of medicinal chemistry, Jul-01, Volume: 42, Issue:13
Structure-activity relationships for substituted bis(acridine-4-carboxamides): a new class of anticancer agents.
AID320269Antiproliferative activity against human SW480 cells after 72 hrs by MTT assay2008Bioorganic & medicinal chemistry, Feb-01, Volume: 16, Issue:3
Synthesis, cytotoxic evaluation, and DNA binding of novel thiazolo[5,4-b]quinoline derivatives.
AID234396Ratio of inhibitory activity against amsacrine resistant jurkat cells to inhibitory activity against wild type human jurkat cells1999Journal of medicinal chemistry, Jul-01, Volume: 42, Issue:13
Structure-activity relationships for substituted bis(acridine-4-carboxamides): a new class of anticancer agents.
AID1149745Toxicity in sc implanted mouse L1210 cells allografted C3H/DBA2 F1 hybrid hybrid mouse assessed as optimum dose required to increase life span treated ip after 24 hrs after tumor inoculation and continued for 5 days1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Potential antitumor agents. 23. 4'-(9-Acridinylamino)alkanesulfonanilide congeners bearing hydrophilic functionality.
AID153557In vivo antitumor activity in mice bearing P388 leukemia cells at an optimal dose of 65 mg/kg given on days 1,5,9.1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Potential antitumor agents. 40. Orally active 4,5-disubstituted derivatives of amsacrine.
AID1453396Inhibition of human topoisomerase-2 at 10 uM using supercoiled pBR322 DNA as substrate after 10 to 15 mins by ethidium bromide staining based electrophoresis relative to control2017Bioorganic & medicinal chemistry, 07-01, Volume: 25, Issue:13
Synthesis and biological research of novel azaacridine derivatives as potent DNA-binding ligands and topoisomerase II inhibitors.
AID20524Relative measure (Rm) of lipophilic/hydrophilic balance from partition chromatography1980Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
Potential antitumor agents. 33. Quantitative structure--activity relationships for mutagenic activity and antitumor activity of substituted 4'-(9-acridinylamino)methanesulfonanilide derivatives.
AID199187Ability to block cleavage of G/GNCC site in Restriction endonuclease Sau961 with the test compound/DNA ratio 1(no. of sites=15); - = no activation1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Properties of the nucleic acid photoaffinity labeling agent 3-azidoamsacrine.
AID1149746Antileukemic activity against sc implanted mouse L1210 cells in C3H/DBA2 F1 hybrid hybrid mouse assessed as increase life span treated ip after 24 hrs after tumor inoculation and continued for 5 days1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Potential antitumor agents. 23. 4'-(9-Acridinylamino)alkanesulfonanilide congeners bearing hydrophilic functionality.
AID1328419Antibacterial activity against wild type Staphylococcus aureus Newman at 5 ug/ml after 16 to 18 hrs2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Accelerating the discovery of antibacterial compounds using pathway-directed whole cell screening.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID383232Cell cycle arrest in human OVCAR-3 cells assessed as accumulation at subG0 phase at 16 uM by flow cytometry2008European journal of medicinal chemistry, Feb, Volume: 43, Issue:2
Discovery of a new anilino-3H-pyrrolo[3,2-f]quinoline derivative as potential anti-cancer agent.
AID85626Ability to block cleavage of GG/CC site in HaeIII enzyme with the test compound/DNA ratio 1(no. of sites=22); - = no activation1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Properties of the nucleic acid photoaffinity labeling agent 3-azidoamsacrine.
AID1453384Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay2017Bioorganic & medicinal chemistry, 07-01, Volume: 25, Issue:13
Synthesis and biological research of novel azaacridine derivatives as potent DNA-binding ligands and topoisomerase II inhibitors.
AID22554Susceptibility to thiolytic cleavage: T1/2 in presence of excess 2-mercaptoethanol1981Journal of medicinal chemistry, May, Volume: 24, Issue:5
Potential antitumor agents. 35. Quantitative relationships between antitumor (L1210) potency and DNA binding for 4'-(9-acridinylamino)methanesulfon-m-anisidide analogues.
AID1328422Inhibition of DltB in ypfP-deficient Staphylococcus aureus RN4220 at 5 ug/ml after 16 to 18 hrs2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Accelerating the discovery of antibacterial compounds using pathway-directed whole cell screening.
AID153029In vivo for optimal dose per day for antitumor activity in P388 cells1983Journal of medicinal chemistry, Nov, Volume: 26, Issue:11
Potential antitumor agents. 38. 3-substituted 5-carboxamido derivatives of amsacrine.
AID657771Cytocidal activity against human HT1080 cells assessed as growth inhibition after 48 hrs by SRB assay2012European journal of medicinal chemistry, Jun, Volume: 52Imidazonaphthyridine systems (part 2): Functionalization of the phenyl ring linked to the pyridine pharmacophore and its replacement by a pyridinone ring produces intriguing differences in cytocidal activity.
AID365817Cytotoxicity against human DLD1 cells by Hoechst test2008Bioorganic & medicinal chemistry, Aug-15, Volume: 16, Issue:16
Design, synthesis and preliminary biological evaluation of acridine compounds as potential agents for a combined targeted chemo-radionuclide therapy approach to melanoma.
AID25575Dissociation constant in aqueous DMF.1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Potential antitumor agents. 41. Analogues of amsacrine with electron-donor substituents in the anilino ring.
AID347897Cytotoxicity against human HL60 cells after 72 hrs by MTT assay2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Synthesis and antitumor activity of novel amsacrine analogs: the critical role of the acridine moiety in determining their biological activity.
AID235013In vitro therapeutic index value is the ratio between IC50 values of [J] and [P]1994Journal of medicinal chemistry, May-13, Volume: 37, Issue:10
Synthesis and in vitro evaluation of 9-anilino-3,6-diaminoacridines active against a multidrug-resistant strain of the malaria parasite Plasmodium falciparum.
AID110723In vitro anticancer activity against B6D2F-1 mice bearing P388 leukemia measured by the average survival time(day+/-SD) at an intravenous dose of 8(mg/kg).. 1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Synthesis and structure-activity relationships of potential anticancer agents: alkylcarbamates of 3-(9-acridinylamino)-5-hydroxymethylaniline.
AID665983Antiproliferative activity against human SF295 cells after 72 hrs by MTT assay2012Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11
Synthesis and cytotoxic activity of new acridine-thiazolidine derivatives.
AID1150556Antitumor activity against mouse L1210 cells allografted in ip dosed C3H/DBA2 F1 mouse assessed as optimum dose required to increase in maximum life span administered as qd for 5 days1976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
Potential antitumor agents. 17. 9-Anilino-10-methylacridinium salts.
AID147018Ability to block cleavage of CC/CGGG site in NciI enzyme with the test compound/DNA ratio 4(no. of sites=10); - = no activation1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Properties of the nucleic acid photoaffinity labeling agent 3-azidoamsacrine.
AID365816Cytotoxicity against mouse B16F0 cells by Hoechst test2008Bioorganic & medicinal chemistry, Aug-15, Volume: 16, Issue:16
Design, synthesis and preliminary biological evaluation of acridine compounds as potential agents for a combined targeted chemo-radionuclide therapy approach to melanoma.
AID1695177Induction of apoptosis in human A549 cells assessed as late apoptotic cells at IC50 concentration after 48 hrs by annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 0.7 %)
AID547840Inhibition of rat aldehyde oxidase2010Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24
Aldehyde oxidase: an enzyme of emerging importance in drug discovery.
AID18955Lipophilicity index (substitution method)1997Journal of medicinal chemistry, Aug-01, Volume: 40, Issue:16
Structure-activity relationships for the antileishmanial and antitrypanosomal activities of 1'-substituted 9-anilinoacridines.
AID665993Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay2012Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11
Synthesis and cytotoxic activity of new acridine-thiazolidine derivatives.
AID97604Tumor cell selectivity determined as maximal percent increase in life span (ILSmax) at LD10 dosage level in L1210 cells1982Journal of medicinal chemistry, Aug, Volume: 25, Issue:8
Structure-antitumor activity relationships of 9-anilinoacridines using pattern recognition.
AID1695176Induction of apoptosis in human A549 cells assessed as early apoptotic cells at IC50 concentration after 48 hrs by annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 0.9 %)
AID146877Ability to block cleavage of GCC/GGC site in NaeI enzyme with the test compound/DNA ratio 1:8(no. of sites=4); - = no activation1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Properties of the nucleic acid photoaffinity labeling agent 3-azidoamsacrine.
AID98378In vitro inhibitory activity against Murine leukemia (L1210)1987Journal of medicinal chemistry, Apr, Volume: 30, Issue:4
Potential antitumor agents. 48. 3'-Dimethylamino derivatives of amsacrine: redox chemistry and in vivo solid tumor activity.
AID20525Lipophilicity (Rm).1987Journal of medicinal chemistry, Sep, Volume: 30, Issue:9
Potential antitumor agents. 52. Carbamate analogues of amsacrine with in vivo activity against multidrug-resistant P388 leukemia.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1500674Antiproliferative activity against human HCT116 cells expressing topoisomerase-1 after 72 hrs by MTT assay2017European journal of medicinal chemistry, Sep-29, Volume: 138Design, synthesis and biological evaluation of 4-amidobenzimidazole acridine derivatives as dual PARP and Topo inhibitors for cancer therapy.
AID657772Cytocidal activity against human HT-29 cells assessed as growth inhibition after 48 hrs by SRB assay2012European journal of medicinal chemistry, Jun, Volume: 52Imidazonaphthyridine systems (part 2): Functionalization of the phenyl ring linked to the pyridine pharmacophore and its replacement by a pyridinone ring produces intriguing differences in cytocidal activity.
AID45745Inhibitory activity of compound for AA8 cells to reduce cell density by 50% (exposed to compound for 4 hours)1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Hypoxia-selective antitumor agents. 2. Electronic effects of 4-substituents on the mechanisms of cytotoxicity and metabolic stability of nitracrine derivatives.
AID210614Compound concentration in mole/kg/day lethal to 10% of mice1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Potential antitumor agents. 36. Quantitative relationships between experimental antitumor activity, toxicity, and structure for the general class of 9-anilinoacridine antitumor agents.
AID91917Inhibitory concentration required to reduce human Jurkat leukemia (JLC sensitive, wild type) cell number to 50% of control cultures1997Journal of medicinal chemistry, Jun-06, Volume: 40, Issue:12
Structure-activity relationships for acridine-substituted analogues of the mixed topoisomerase I/II inhibitor N-[2-(dimethylamino)ethyl]acridine-4-carboxamide.
AID144936Inhibitory activity against NCI-H226 cell line using MTT assay(mutant p53)2000Journal of medicinal chemistry, Apr-20, Volume: 43, Issue:8
Antitumor polycyclic acridines. 7. Synthesis and biological properties of DNA affinic tetra- and pentacyclic acridines.
AID1150557Antitumor activity against mouse L1210 cells allografted in C3H/DBA2 F1 mouse assessed as increase in life span at optimum dose, ip qd administered for 5 days relative to control1976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
Potential antitumor agents. 17. 9-Anilino-10-methylacridinium salts.
AID54266Micelle-bound drug concentration in 0.1 SHE buffer at the concentration of 50 uM for equilibrium binding to calf thymus DNA1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Kinetic and equilibrium binding studies of amsacrine-4-carboxamides: a class of asymmetrical DNA-intercalating agents which bind by threading through the DNA helix.
AID226888Ratio of inhibitory concentration of Human Jurkat leukemia A (JLA) and Human Jurkat leukemia C (JLC)1997Journal of medicinal chemistry, Jun-20, Volume: 40, Issue:13
Synthesis and antitumor properties of N-[2-(dimethylamino)ethyl]carboxamide derivatives of fused tetracyclic quinolines and quinoxalines: a new class of putative topoisomerase inhibitors.
AID232616Ratio of IC50 against murine leukemia cells (L1210) to that of IC50 against colon tumor cells (HCT-8)1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Potential antitumor agents. 47. 3'-Methylamino analogues of amsacrine with in vivo solid tumor activity.
AID1434047Inhibition of recombinant human topoisomerase-2alpha mediated DNA ligation expressed in Saccharomyces cerevisiae JEL1 harboring topoisomerase1 deletion mutant at 50 uM measured after 6 mins by ethidium bromide staining based agarose gel electrophoresis2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Novel trifluoromethylated 9-amino-3,4-dihydroacridin-1(2H)-ones act as covalent poisons of human topoisomerase IIα.
AID1719208Inhibition of Saccharomyces cerevisiae DNA topoisomerase 2 assessed as decrease in relaxation of supercoiled DNA using supercoiled pBR322 plasmid DNA at 100 to 150 uM gel electrophoresis method2021Bioorganic & medicinal chemistry letters, 03-01, Volume: 35A new 1-nitro-9-aminoacridine derivative targeting yeast topoisomerase II able to overcome fluconazole-resistance.
AID426114Inhibition of human recombinant topoisomerase 2 assessed as induction of linear pBR322 DNA formation at 15 uM by agarose gel electrophoresis2009European journal of medicinal chemistry, Jul, Volume: 44, Issue:7
DNA-targeting pyrroloquinoline-linked butenone and chalcones: synthesis and biological evaluation.
AID396406Antiproliferative activity against human HT1080 cells after 48 hrs by SRB assay2008European journal of medicinal chemistry, Nov, Volume: 43, Issue:11
Novel imidazo[1,2-a]naphthyridinic systems (part 1): synthesis, antiproliferative and DNA-intercalating activities.
AID1601656Poison activity at recombinant human topoisomerase-2 assessed as stabilization of covalent topo-2-DNA cleavage complex by measuring linear DNA formation at 10 uM using supercoiled pBR322 DNA as substrate after 60 mins by agarose gel electrophoresis method2019European journal of medicinal chemistry, Mar-01, Volume: 165Benzothiopyranoindole- and pyridothiopyranoindole-based antiproliferative agents targeting topoisomerases.
AID107797Induction frequency for L5178Y cells was evaluated at dose 0.005 mg/mL in dark condition (expt-II)1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Properties of the nucleic acid photoaffinity labeling agent 3-azidoamsacrine.
AID1133945Antitumor activity against mouse L1210 cells subcutaneously xenografted in ip dosed C3H/DBA2 F1 hybrid mouse assessed as increase in host lifespan administered daily for 5 days starting 24 hrs post-tumor implantation1977Journal of medicinal chemistry, Apr, Volume: 20, Issue:4
Potential antitumor agents. 22. Latentiated congeners of the 4'-(9-acridinylamino)methanesulfonanilides.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1577586Inhibition of EtBr binding to calf thymus DNA measured after 30 mins by fluorescence assay2019Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17
Discovery and Biological Evaluations of Halogenated 2,4-Diphenyl Indeno[1,2-
AID1434038Poison activity at recombinant human topoisomerase-2alpha expressed in Saccharomyces cerevisiae JEL1 harboring topoisomerase1 deletion mutant assessed as increase in double stranded DNA cleavage at 50 uM using supercoiled pBR322 DNA as substrate in presen2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Novel trifluoromethylated 9-amino-3,4-dihydroacridin-1(2H)-ones act as covalent poisons of human topoisomerase IIα.
AID120024Average tumor volume of the B-16 melanoma1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
9-substituted acridine derivatives with long half-life and potent antitumor activity: synthesis and structure-activity relationships.
AID1145945Cytotoxicity against mouse L1210 cells assessed as growth inhibition at 0.1 ug/ml after 48 hrs1976Journal of medicinal chemistry, Aug, Volume: 19, Issue:8
Synthesis and biological properties of some spin-labeled 9-aminoacridines.
AID683863Inhibition of human topoisomerase 2-mediated [3H]TdR-labeled catenated kinetoplast DNA decatenation after 15 to 30 mins by scintillation counting2012Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19
New derivatives of 11-methyl-6-[2-(dimethylamino)ethyl]-6H-indolo[2,3-b]quinoline as cytotoxic DNA topoisomerase II inhibitors.
AID1145939Cytotoxicity against mouse L1210 cells assessed as growth inhibition at 100 ug/ml after 48 hrs1976Journal of medicinal chemistry, Aug, Volume: 19, Issue:8
Synthesis and biological properties of some spin-labeled 9-aminoacridines.
AID116329In vitro anticancer activity against B6D2F-1 mice bearing P388 leukemia measured by the increase in lifespan(%) at an intravenous dose of 18(mg/kg).1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Synthesis and structure-activity relationships of potential anticancer agents: alkylcarbamates of 3-(9-acridinylamino)-5-hydroxymethylaniline.
AID80680Cytotoxicity against HCT116 cells.1995Journal of medicinal chemistry, Oct-27, Volume: 38, Issue:22
Topoisomerase II-mediated DNA cleavage by adocia- and xestoquinones from the Philippine sponge Xestospongia sp.
AID225924Association constant for binding to poly(dG-dC) DNA in 0.01 SHE buffer, measured by ethidium displacement method1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Kinetic and equilibrium binding studies of amsacrine-4-carboxamides: a class of asymmetrical DNA-intercalating agents which bind by threading through the DNA helix.
AID1363198Inhibition of EtBr binding to calf thymus DNA up to 40 uM by fluorescence spectroscopy2018Bioorganic & medicinal chemistry, 10-01, Volume: 26, Issue:18
A new phenolic series of indenopyridinone as topoisomerase inhibitors: Design, synthesis, and structure-activity relationships.
AID57199In vitro inhibition of partially purified human ovarian carcinoma topoisomerase II of kDNA decatenation1995Journal of medicinal chemistry, Oct-27, Volume: 38, Issue:22
Topoisomerase II-mediated DNA cleavage by adocia- and xestoquinones from the Philippine sponge Xestospongia sp.
AID487000Binding affinity to calf thymus DNA assessed as ratio of final absorbance area to the absorbance at 100 uM after 24 hrs by UV spectrophotometer analysis relative to control2010Bioorganic & medicinal chemistry, Jun-15, Volume: 18, Issue:12
Study of benzo[a]phenazine 7,12-dioxide as selective hypoxic cytotoxin-scaffold. Identification of aerobic-antitumoral activity through DNA fragmentation.
AID107803Relative mutation induction for L5178Y cells was evaluated at dose 0.005 mg/mL in dark condition (expt-II)1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Properties of the nucleic acid photoaffinity labeling agent 3-azidoamsacrine.
AID152882Percent increase in life span of the drug-treated tumor-bearing animals vs nontreated tumor-bearing controls with P388 leukemia cells.1987Journal of medicinal chemistry, Sep, Volume: 30, Issue:9
Potential antitumor agents. 52. Carbamate analogues of amsacrine with in vivo activity against multidrug-resistant P388 leukemia.
AID25818Ionisation constant (pKa)1981Journal of medicinal chemistry, May, Volume: 24, Issue:5
Potential antitumor agents. 35. Quantitative relationships between antitumor (L1210) potency and DNA binding for 4'-(9-acridinylamino)methanesulfon-m-anisidide analogues.
AID162407Antitumor activity as association constant for DNA binding to poly (dA.dT)1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Potential antitumor agents. 37. Organophosphorus derivatives of 9-anilinoacridine.
AID117342Percentage increase in life span of drug-treated tumor bearing controls was determined1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Potential antitumor agents. 41. Analogues of amsacrine with electron-donor substituents in the anilino ring.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID53293Compound was tested for DNA Topoisomerase II mediated cleavage of DNA; Each (+) indicates 1 to 2 -fold increase1981Journal of medicinal chemistry, May, Volume: 24, Issue:5
New analgesic drugs derived from phencyclidine.
AID665994Antiproliferative activity against human K562 cells after 72 hrs by MTT assay2012Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11
Synthesis and cytotoxic activity of new acridine-thiazolidine derivatives.
AID131484In vivo increased lifespan in mice implanted intraperitoneally with wild type P388 murine leukemia cell line at the optimal dose of 13.3 mg/kg/day1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Potential antitumor agents. 59. Structure-activity relationships for 2-phenylbenzimidazole-4-carboxamides, a new class of "minimal" DNA-intercalating agents which may not act via topoisomerase II.
AID1610466Antiproliferative against human CCRF-CEM cells incubated for 72 hrs by MTT assay2019Bioorganic & medicinal chemistry letters, 12-01, Volume: 29, Issue:23
Design, synthesis and biological research of novel N-phenylbenzamide-4-methylamine acridine derivatives as potential topoisomerase I/II and apoptosis-inducing agents.
AID665979Antiproliferative activity against human MDA-MB-435 cells after 72 hrs by MTT assay2012Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11
Synthesis and cytotoxic activity of new acridine-thiazolidine derivatives.
AID54265Free drug concentration in 0.1 SHE buffer at the concentration of 50 uM; 9.4 x 10 e-3 epcilonfor equilibrium binding to calf thymus DNA1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Kinetic and equilibrium binding studies of amsacrine-4-carboxamides: a class of asymmetrical DNA-intercalating agents which bind by threading through the DNA helix.
AID85628Ability to block cleavage of GG/CC site in HaeIII enzyme with the test compound/DNA ratio 4(no. of sites=22); - = no activation1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Properties of the nucleic acid photoaffinity labeling agent 3-azidoamsacrine.
AID1148476Toxicity in ip dosed BDF1 mouse allografted with mouse L1210 cells administered qd for 5 days1978Journal of medicinal chemistry, Jul, Volume: 21, Issue:7
Potenial antitumor agents. 28. Deoxyribonucleic acid polyintercalating agents.
AID130507Percent increase in life span of the drug treated tumor bearing animals vs nontreated tumor bearing controls was determined against P388/ADR cells;NA= not active1987Journal of medicinal chemistry, Sep, Volume: 30, Issue:9
Potential antitumor agents. 52. Carbamate analogues of amsacrine with in vivo activity against multidrug-resistant P388 leukemia.
AID146878Ability to block cleavage of GCC/GGC site in NaeI enzyme with the test compound/DNA ratio 4(no. of sites=4); - = no activation1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Properties of the nucleic acid photoaffinity labeling agent 3-azidoamsacrine.
AID100911Concentration required to reduce incorporation of [3H]TdR in drug-treated cultures of intracellular Leishmania major to 50% of controls1997Journal of medicinal chemistry, Aug-01, Volume: 40, Issue:16
Structure-activity relationships for the antileishmanial and antitrypanosomal activities of 1'-substituted 9-anilinoacridines.
AID88458Ability to block cleavage of G/ANTC site in Hinf1 enzyme with the test compound/DNA ratio 1:8(no. of sites=10); - = no activation1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Properties of the nucleic acid photoaffinity labeling agent 3-azidoamsacrine.
AID100240Inhibitory concentration required to reduce Lewis lung carcinoma cell number to 50% of control cultures1997Journal of medicinal chemistry, Jun-06, Volume: 40, Issue:12
Structure-activity relationships for acridine-substituted analogues of the mixed topoisomerase I/II inhibitor N-[2-(dimethylamino)ethyl]acridine-4-carboxamide.
AID365810Cytotoxicity against human M4Beu cells by resazurin reduction test2008Bioorganic & medicinal chemistry, Aug-15, Volume: 16, Issue:16
Design, synthesis and preliminary biological evaluation of acridine compounds as potential agents for a combined targeted chemo-radionuclide therapy approach to melanoma.
AID1434039Poison activity at recombinant human topoisomerase-2alpha expressed in Saccharomyces cerevisiae JEL1 harboring topoisomerase1 deletion mutant assessed as concentration required to triple the level of DNA cleavage complex relative to basal level using supe2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Novel trifluoromethylated 9-amino-3,4-dihydroacridin-1(2H)-ones act as covalent poisons of human topoisomerase IIα.
AID103470In vivo for antitumor activity against Lewis lung carcinoma1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Potential antitumor agents. 47. 3'-Methylamino analogues of amsacrine with in vivo solid tumor activity.
AID576615Growth inhibition in human HeLa cells after 72 hrs by trypan blue assay2011Bioorganic & medicinal chemistry, Feb-01, Volume: 19, Issue:3
Benzoquinazoline derivatives as new agents affecting DNA processing.
AID47006The compound was tested for the cytotoxicity against human leukemic CEM/VM-1 cell lines1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
9-substituted acridine derivatives with long half-life and potent antitumor activity: synthesis and structure-activity relationships.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID665985Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay2012Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11
Synthesis and cytotoxic activity of new acridine-thiazolidine derivatives.
AID26314pKa value determined spectrophotometrically in 20% aqueous DMF1983Journal of medicinal chemistry, Nov, Volume: 26, Issue:11
Potential antitumor agents. 38. 3-substituted 5-carboxamido derivatives of amsacrine.
AID10004Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Novel acridine-triazenes as prototype combilexins: synthesis, DNA binding, and biological activity.
AID116332In vitro anticancer activity against B6D2F-1 mice bearing P388 leukemia measured by the increase in lifespan(%) at an intravenous dose of 8(mg/kg).. 1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Synthesis and structure-activity relationships of potential anticancer agents: alkylcarbamates of 3-(9-acridinylamino)-5-hydroxymethylaniline.
AID124470In vitro anticancer activity against B6D2F-1 mice bearing P388 leukemia measured by the toxicity death at an intravenous dose of 8(mg/kg).. 1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Synthesis and structure-activity relationships of potential anticancer agents: alkylcarbamates of 3-(9-acridinylamino)-5-hydroxymethylaniline.
AID1148374Antitumor activity against mouse L1210 cells transfected in ip dosed C3H/DBA2 F1 mouse qd administered for 5 days1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Potential antitumor agents. 26. Anionic congeners of the 9-anilinoacridines.
AID85627Ability to block cleavage of GG/CC site in HaeIII enzyme with the test compound/DNA ratio 1:8(no. of sites=22); - = no activation1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Properties of the nucleic acid photoaffinity labeling agent 3-azidoamsacrine.
AID665989Antiproliferative activity against human HCT15 cells after 72 hrs by MTT assay2012Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11
Synthesis and cytotoxic activity of new acridine-thiazolidine derivatives.
AID95454Concentration required to reduce growth of human jurkat leukemia cells to 50% of control cultures, determined using a 72 hr continuous exposure1994Journal of medicinal chemistry, May-13, Volume: 37, Issue:10
Synthesis and in vitro evaluation of 9-anilino-3,6-diaminoacridines active against a multidrug-resistant strain of the malaria parasite Plasmodium falciparum.
AID1472943Induction of relaxed pBluescript SK(+) DNA intercalation (unknown origin) assessed as negative supercoiling at 50 uM after 15 mins by agarose gel electrophoresis method2018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
Neutral Porphyrin Derivative Exerts Anticancer Activity by Targeting Cellular Topoisomerase I (Top1) and Promotes Apoptotic Cell Death without Stabilizing Top1-DNA Cleavage Complexes.
AID43838The compound was tested for the cytotoxicity against human leukemic CCRF-CEM cell lines1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
9-substituted acridine derivatives with long half-life and potent antitumor activity: synthesis and structure-activity relationships.
AID477295Octanol-water partition coefficient, log P of the compound2010European journal of medicinal chemistry, Apr, Volume: 45, Issue:4
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
AID153024In vivo for antitumor activity against P388 leukemia.1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Potential antitumor agents. 47. 3'-Methylamino analogues of amsacrine with in vivo solid tumor activity.
AID678718Metabolic stability in human liver microsomes assessed as high signal/noise ratio (S/N of >100) by measuring GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1609087Binding affinity to salmon sperm single stranded DNA assessed as DNA intercalation by measuring increase in viscosity at 12 to 60 uM by viscometric method2019European journal of medicinal chemistry, Nov-15, Volume: 182Novel 4-quinoline-thiosemicarbazone derivatives: Synthesis, antiproliferative activity, in vitro and in silico biomacromolecule interaction studies and topoisomerase inhibition.
AID107804Relative mutation induction for L5178Y cells was evaluated at dose 0.005 mg/mL in light condition (expt-II)1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Properties of the nucleic acid photoaffinity labeling agent 3-azidoamsacrine.
AID678715Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID51931Tested for the cytotoxicity against the repair deficient xrs-6 chinese hamster ovary cell line1994Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22
Inhibition of topoisomerase II catalytic activity by pyridoacridine alkaloids from a Cystodytes sp. ascidian: a mechanism for the apparent intercalator-induced inhibition of topoisomerase II.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID65960Ability to block cleavage of TTT/AAA site in DraI enzyme with the test compound/DNA ratio 1:8(no. of sites=3); - = no activation1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Properties of the nucleic acid photoaffinity labeling agent 3-azidoamsacrine.
AID1396991Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay2018Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14
Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1148373Lipopholic-hydrophilic balance, Rm of the compound by reversed-phase chromatography1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Potential antitumor agents. 26. Anionic congeners of the 9-anilinoacridines.
AID201229Concentration of drug needed to kill Salmonella Typhimurium strain TA 1537 grown on histidine-enriched medium1980Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
Potential antitumor agents. 33. Quantitative structure--activity relationships for mutagenic activity and antitumor activity of substituted 4'-(9-acridinylamino)methanesulfonanilide derivatives.
AID365814Cytotoxicity against mouse B16F0 cells by resazurin reduction test2008Bioorganic & medicinal chemistry, Aug-15, Volume: 16, Issue:16
Design, synthesis and preliminary biological evaluation of acridine compounds as potential agents for a combined targeted chemo-radionuclide therapy approach to melanoma.
AID355580Antiproliferative activity against human HT-29 cells at 1 ug after 48 hrs by two-layer agar-diffusion method
AID1145944Cytotoxicity against mouse L1210 cells assessed as growth inhibition at 0.1 ug/ml after 24 hrs1976Journal of medicinal chemistry, Aug, Volume: 19, Issue:8
Synthesis and biological properties of some spin-labeled 9-aminoacridines.
AID227361Compound was tested for topoisomerase mediated cleavage of DNA; Each + indicates a 2 to 4 fold increase1981Journal of medicinal chemistry, May, Volume: 24, Issue:5
New analgesic drugs derived from phencyclidine.
AID665986Antiproliferative activity against human Hs578T cells after 72 hrs by MTT assay2012Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11
Synthesis and cytotoxic activity of new acridine-thiazolidine derivatives.
AID103274Inhibitory activity against MCF7wt cell line using MTT assay2000Journal of medicinal chemistry, Apr-20, Volume: 43, Issue:8
Antitumor polycyclic acridines. 7. Synthesis and biological properties of DNA affinic tetra- and pentacyclic acridines.
AID326626Cytotoxicity against human MCF7 cells by XTT assay2008Bioorganic & medicinal chemistry, Mar-01, Volume: 16, Issue:5
Synthesis and antiproliferative activity of benzyl and phenethyl analogs of makaluvamines.
AID678717Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID55650Time constant describing the association profile of calf thymus DNA-drug complexes in 0.1 SHE buffer at 20 degree C after 1 min; too fast to measure1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Kinetic and equilibrium binding studies of amsacrine-4-carboxamides: a class of asymmetrical DNA-intercalating agents which bind by threading through the DNA helix.
AID665984Antiproliferative activity against human MX1 cells after 72 hrs by MTT assay2012Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11
Synthesis and cytotoxic activity of new acridine-thiazolidine derivatives.
AID320270Antiproliferative activity against human SW620 cells after 72 hrs by MTT assay2008Bioorganic & medicinal chemistry, Feb-01, Volume: 16, Issue:3
Synthesis, cytotoxic evaluation, and DNA binding of novel thiazolo[5,4-b]quinoline derivatives.
AID55121Binding constant (log K) for DNA binding by ethidium bromide displacement1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Potential antitumor agents. 47. 3'-Methylamino analogues of amsacrine with in vivo solid tumor activity.
AID145200Inhibitory activity against NCI-H322 cell line using MTT assay(mutant p53)2000Journal of medicinal chemistry, Apr-20, Volume: 43, Issue:8
Antitumor polycyclic acridines. 7. Synthesis and biological properties of DNA affinic tetra- and pentacyclic acridines.
AID1453385Antiproliferative activity against human U937 cells after 48 hrs by MTT assay2017Bioorganic & medicinal chemistry, 07-01, Volume: 25, Issue:13
Synthesis and biological research of novel azaacridine derivatives as potent DNA-binding ligands and topoisomerase II inhibitors.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID355287DNA damaging activity against RAD52 DNA repair gene deficient Saccharomyces cerevisiae mutant assessed as drug level required to produce 12 mm zone of inhibition assessed per 100 uL after 48 hrs1997Journal of natural products, Oct, Volume: 60, Issue:10
Three new pseudodistomins, piperidine alkaloids from the ascidian Pseudodistoma megalarva.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID100239Inhibitory concentration against Murine Lewis lung carcinoma (LLC) cell proliferation1997Journal of medicinal chemistry, Jun-20, Volume: 40, Issue:13
Synthesis and antitumor properties of N-[2-(dimethylamino)ethyl]carboxamide derivatives of fused tetracyclic quinolines and quinoxalines: a new class of putative topoisomerase inhibitors.
AID1197848Stabilization of recombinant human topoisomerase 2-pBR322 DNA cleavage complex assessed as linear DNA formation at 10 uM after 60 mins by agarose gel electrophoresis2015European journal of medicinal chemistry, Mar-06, Volume: 92Boehmeriasin A as new lead compound for the inhibition of topoisomerases and SIRT2.
AID665990Antiproliferative activity against human SW620 cells after 72 hrs by MTT assay2012Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11
Synthesis and cytotoxic activity of new acridine-thiazolidine derivatives.
AID1544064Displacement of ethidium bromide from calf thymus DNA at 50 uM by fluorescence assay2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Discovery and Mechanistic Study of Tailor-Made Quinoline Derivatives as Topoisomerase 1 Poison with Potent Anticancer Activity.
AID240619Inhibitory concentration against cytochrome P450 2D62004Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22
Validation of model of cytochrome P450 2D6: an in silico tool for predicting metabolism and inhibition.
AID91017Ability to block cleavage of C/CGG site in HpaII enzyme with the test compound/DNA ratio 1(no. of sites=26); - = no activation1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Properties of the nucleic acid photoaffinity labeling agent 3-azidoamsacrine.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID229741Hypersensitivity factor (HF) of IC50 (AA8) / IC50 (EM-9) of compound for repair deffective mutants1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Hypoxia-selective antitumor agents. 2. Electronic effects of 4-substituents on the mechanisms of cytotoxicity and metabolic stability of nitracrine derivatives.
AID96646Concentration for inhibiting the growth of L1210 cells by 50% over 3 days was determined1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Potential antitumor agents. 37. Organophosphorus derivatives of 9-anilinoacridine.
AID152866Percent increase in the life span of treated mice over a group of control mice injected with p388 tumor alone when administered intraperitoneally (9) as a solution in 0.1 mL of 30%,v/v, ethanol/water1983Journal of medicinal chemistry, Nov, Volume: 26, Issue:11
Potential antitumor agents. 39. Anilino ring geometry of amsacrine and derivatives: relationship to DNA binding and antitumor activity.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1428710Induction of calf thymus DNA intercalation assessed as inhibition of ethidium bromide binding to DNA after 30 mins by fluorescence assay2017European journal of medicinal chemistry, Feb-15, Volume: 127Rational design, synthesis, and evaluation of novel 2,4-Chloro- and Hydroxy-Substituted diphenyl Benzofuro[3,2-b]Pyridines: Non-intercalative catalytic topoisomerase I and II dual inhibitor.
AID234397Ratio of inhibitory activity against doxorubicin resistant jurkat cells to inhibitory activity against wild type human jurkat cells1999Journal of medicinal chemistry, Jul-01, Volume: 42, Issue:13
Structure-activity relationships for substituted bis(acridine-4-carboxamides): a new class of anticancer agents.
AID96372Inhibition of KB cell growth in vitro1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
Synthesis and antitumor activity of fused tetracyclic quinoline derivatives. 1.
AID96210Percent fluorescence of the ethidium bromide-DNA complex1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
Synthesis and antitumor activity of fused tetracyclic quinoline derivatives. 1.
AID1145946Cytotoxicity against mouse L1210 cells assessed as growth inhibition at 0.01 ug/ml after 24 hrs1976Journal of medicinal chemistry, Aug, Volume: 19, Issue:8
Synthesis and biological properties of some spin-labeled 9-aminoacridines.
AID365812Cytotoxicity against human DLD1 cells by resazurin reduction test2008Bioorganic & medicinal chemistry, Aug-15, Volume: 16, Issue:16
Design, synthesis and preliminary biological evaluation of acridine compounds as potential agents for a combined targeted chemo-radionuclide therapy approach to melanoma.
AID229289Ratio of IC50 of Jurkat leukemia amsacrine (JLA) to the IC50 of Jurkat leukemia (JLC sensitive, wild type)1997Journal of medicinal chemistry, Jun-06, Volume: 40, Issue:12
Structure-activity relationships for acridine-substituted analogues of the mixed topoisomerase I/II inhibitor N-[2-(dimethylamino)ethyl]acridine-4-carboxamide.
AID55652Time constant describing the association profile of calf thymus DNA-drug complexes in 0.1 SHE buffer at 20 degree C after 2 min; too fast to measure1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Kinetic and equilibrium binding studies of amsacrine-4-carboxamides: a class of asymmetrical DNA-intercalating agents which bind by threading through the DNA helix.
AID1609092Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay2019European journal of medicinal chemistry, Nov-15, Volume: 182Novel 4-quinoline-thiosemicarbazone derivatives: Synthesis, antiproliferative activity, in vitro and in silico biomacromolecule interaction studies and topoisomerase inhibition.
AID365811Cytotoxicity against human fibroblast cells by resazurin reduction test2008Bioorganic & medicinal chemistry, Aug-15, Volume: 16, Issue:16
Design, synthesis and preliminary biological evaluation of acridine compounds as potential agents for a combined targeted chemo-radionuclide therapy approach to melanoma.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID150659Inhibitory activity against P388 murine leukemia cells2001Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12
Synthesis and cytotoxic activity of 7-oxo-7H-dibenz[f,ij]isoquinoline and 7-oxo-7H-benzo[e]perimidine derivatives.
AID210610In vitro therapeutic index calculated as the IC50 ratio of Jurkat cells to that of Leishmania major.1997Journal of medicinal chemistry, Aug-01, Volume: 40, Issue:16
Structure-activity relationships for the antileishmanial and antitrypanosomal activities of 1'-substituted 9-anilinoacridines.
AID143043Inhibitory activity against NCI-H460 cell line using MTT assay(Wild type p53)2000Journal of medicinal chemistry, Apr-20, Volume: 43, Issue:8
Antitumor polycyclic acridines. 7. Synthesis and biological properties of DNA affinic tetra- and pentacyclic acridines.
AID355585Antiproliferative activity against mouse P388 cells at 0.1 ug after 48 hrs by two-layer agar-diffusion method
AID55630Induced change in DNA-melting (deltaTm) with [poly(dA-dT)]2 at pH 65.01995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Novel acridine-triazenes as prototype combilexins: synthesis, DNA binding, and biological activity.
AID225781Association constant for binding to poly(dA-dT) DNA in 0.01 SHE buffer, measured by ethidium displacement method1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Kinetic and equilibrium binding studies of amsacrine-4-carboxamides: a class of asymmetrical DNA-intercalating agents which bind by threading through the DNA helix.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID347893Cytotoxicity against human A431 cells after 72 hrs by MTT assay2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Synthesis and antitumor activity of novel amsacrine analogs: the critical role of the acridine moiety in determining their biological activity.
AID35546Ability to block cleavage of AG/CT site in AluI enzyme with the test compound, DNA ratio 1:8(no. of sites=16); - = no activation1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Properties of the nucleic acid photoaffinity labeling agent 3-azidoamsacrine.
AID103073Inhibitory activity against MCF-7 wt cell line using MTT assay (ER+,pgR+,wildtype p53)2000Journal of medicinal chemistry, Apr-20, Volume: 43, Issue:8
Antitumor polycyclic acridines. 7. Synthesis and biological properties of DNA affinic tetra- and pentacyclic acridines.
AID25353Compound was evaluated for its rate of absorption from the intestine and pKa value was determined, lower value indicate high absorption from gastrointestinal tract. 1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Potential antitumor agents. 40. Orally active 4,5-disubstituted derivatives of amsacrine.
AID1396990Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay2018Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14
Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors.
AID103617In vivo for antitumor activity against Lewis lung carcinoma1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Potential antitumor agents. 47. 3'-Methylamino analogues of amsacrine with in vivo solid tumor activity.
AID57198In vitro 50% inhibition of topoisomerase II mediated k-DNA decatenation1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
9-substituted acridine derivatives with long half-life and potent antitumor activity: synthesis and structure-activity relationships.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1453386Antiproliferative activity against human A549 cells after 48 hrs by MTT assay2017Bioorganic & medicinal chemistry, 07-01, Volume: 25, Issue:13
Synthesis and biological research of novel azaacridine derivatives as potent DNA-binding ligands and topoisomerase II inhibitors.
AID238250Binding affinity for cytochrome P450 2D62004Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22
Validation of model of cytochrome P450 2D6: an in silico tool for predicting metabolism and inhibition.
AID130488% increase in life span of treated mice over control groups injected with P388 cells alone1983Journal of medicinal chemistry, Nov, Volume: 26, Issue:11
Potential antitumor agents. 38. 3-substituted 5-carboxamido derivatives of amsacrine.
AID124471In vitro anticancer activity against B6D2F-1 mice bearing P388 leukemia measured by the toxicity death at an intravenous dose of 12(mg/kg).1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Synthesis and structure-activity relationships of potential anticancer agents: alkylcarbamates of 3-(9-acridinylamino)-5-hydroxymethylaniline.
AID150522In vitro cell growth inhibitory activity against wild type P388 murine leukemia cell line (P388/W)1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Potential antitumor agents. 59. Structure-activity relationships for 2-phenylbenzimidazole-4-carboxamides, a new class of "minimal" DNA-intercalating agents which may not act via topoisomerase II.
AID1507348Inhibition of recombinant human topoisomerase-2alpha assessed as reducton in relaxation of supercoiled pUC19 DNA at 50 to 100 uM after 30 mins by ethidium bromide staining-based gel electrophoresis assay2017European journal of medicinal chemistry, Aug-18, Volume: 136Thiosemicarbazones and 4-thiazolidinones indole-based derivatives: Synthesis, evaluation of antiproliferative activity, cell death mechanisms and topoisomerase inhibition assay.
AID133779Maximum tolerated dose administarted iv (mg/kg) to mice1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
Synthesis and antitumor activity of 4-aminomethylthioxanthenone and 5-aminomethylbenzothiopyranoindazole derivatives.
AID211282Unwinding of DNA observed in a reaction mixture containing PBR322 DNA dimer, calf thymus DNA topoisomerase II, and the drug; ++ = unwinding was observed at 25 ug/mL1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
Synthesis and antitumor activity of fused tetracyclic quinoline derivatives. 1.
AID547838Inhibition of human aldehyde oxidase2010Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24
Aldehyde oxidase: an enzyme of emerging importance in drug discovery.
AID576623Stabilization of supercoiled pBR322 DNA-human recombinant topoisomerase 2 complex assessed as linear DNA formation at 8 uM after 60 mins2011Bioorganic & medicinal chemistry, Feb-01, Volume: 19, Issue:3
Benzoquinazoline derivatives as new agents affecting DNA processing.
AID576613Growth inhibition in human HL60 cells after 72 hrs by trypan blue assay2011Bioorganic & medicinal chemistry, Feb-01, Volume: 19, Issue:3
Benzoquinazoline derivatives as new agents affecting DNA processing.
AID386625Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells by confocal microscopy2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
AID55137DNA binding affinity as log K value1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Potential antitumor agents. 40. Orally active 4,5-disubstituted derivatives of amsacrine.
AID665980Antiproliferative activity against human OVCAR8 cells after 72 hrs by MTT assay2012Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11
Synthesis and cytotoxic activity of new acridine-thiazolidine derivatives.
AID1274496Binding affinity to Escherichia coli pBR322 DNA assessed as intercalation of pBR322 DNA at 0.1 to 100 uM by fluorescence based ethidium bromide displacement assay2016Journal of medicinal chemistry, Jan-14, Volume: 59, Issue:1
Synthesis and Mechanism Studies of 1,3-Benzoazolyl Substituted Pyrrolo[2,3-b]pyrazine Derivatives as Nonintercalative Topoisomerase II Catalytic Inhibitors.
AID1133946Antitumor activity against mouse L1210 cells intraperitoneally xenografted in ip dosed C3H/DBA2 F1 hybrid mouse assessed as increase in host lifespan administered daily for 5 days starting 24 hrs post-tumor implantation1977Journal of medicinal chemistry, Apr, Volume: 20, Issue:4
Potential antitumor agents. 22. Latentiated congeners of the 4'-(9-acridinylamino)methanesulfonanilides.
AID158039Inhibitory concentration IC50 against Plasmodium falciparum K1 by [3H]hypoxanthine uptake over 24 hr1994Journal of medicinal chemistry, May-13, Volume: 37, Issue:10
Synthesis and in vitro evaluation of 9-anilino-3,6-diaminoacridines active against a multidrug-resistant strain of the malaria parasite Plasmodium falciparum.
AID153537Optimal dose required to inhibit the P388/ADR cells in vivo after intraperitoneal administration.1987Journal of medicinal chemistry, Sep, Volume: 30, Issue:9
Potential antitumor agents. 52. Carbamate analogues of amsacrine with in vivo activity against multidrug-resistant P388 leukemia.
AID1294879Binding affinity to calf thymus DNA after 5 mins by UV-vis spectrophotometry2016European journal of medicinal chemistry, Jun-30, Volume: 116Synthesis and antiproliferative activity of 9-benzylamino-6-chloro-2-methoxy-acridine derivatives as potent DNA-binding ligands and topoisomerase II inhibitors.
AID665992Antiproliferative activity against human HCT8 cells after 72 hrs by MTT assay2012Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11
Synthesis and cytotoxic activity of new acridine-thiazolidine derivatives.
AID26064Ionization constant (pKa)1980Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
Potential antitumor agents. 33. Quantitative structure--activity relationships for mutagenic activity and antitumor activity of substituted 4'-(9-acridinylamino)methanesulfonanilide derivatives.
AID1695169Cytotoxicity against unstimulated human blood Leucocytes assessed as cell viability at 25 to 100 uM incubated for 24 to 72 hrs by MTT assay
AID96566Inhibitory concentration against L1210 leukemic cell proliferation over 24 hr1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Novel acridine-triazenes as prototype combilexins: synthesis, DNA binding, and biological activity.
AID103447Evaluated in vivo for antitumor activity against Lewis lung carcinoma; g denotes ILS of 50% could not be reached at any dose level1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Potential antitumor agents. 47. 3'-Methylamino analogues of amsacrine with in vivo solid tumor activity.
AID355586Antiproliferative activity against mouse P388 cells at 0.01 ug after 48 hrs by two-layer agar-diffusion method
AID382901Cell cycle arrest in human CCRF-CEM cells assessed as accumulation at G2/M phase at 1 time IC50 after 24 hrs by flow cytometry2008Bioorganic & medicinal chemistry, Apr-15, Volume: 16, Issue:8
DNA threading bis(9-aminoacridine-4-carboxamides): effects of piperidine sidechains on DNA binding, cytotoxicity and cell cycle arrest.
AID57063In vitro inhibitior of human DNA topoisomerase II from HeLa cells.1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
Synthesis and antitumor activity of 4-aminomethylthioxanthenone and 5-aminomethylbenzothiopyranoindazole derivatives.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID78992In vitro for cytotoxicity against human colon tumor cells (HCT-8) in culture1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Potential antitumor agents. 47. 3'-Methylamino analogues of amsacrine with in vivo solid tumor activity.
AID134219The log cell kill of tumor-bearing mice, based on tumor growth delay.1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
Synthesis and antitumor activity of 4-aminomethylthioxanthenone and 5-aminomethylbenzothiopyranoindazole derivatives.
AID547842Inhibition of rabbit aldehyde oxidase2010Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24
Aldehyde oxidase: an enzyme of emerging importance in drug discovery.
AID1149747Antileukemic activity against ip implanted mouse L1210 cells in C3H/DBA2 F1 hybrid hybrid mouse assessed as increase life span treated ip after 24 hrs after tumor inoculation and continued for 5 days1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Potential antitumor agents. 23. 4'-(9-Acridinylamino)alkanesulfonanilide congeners bearing hydrophilic functionality.
AID139092Drug dose in (mg/kg)/day to provide an increase in life span of 40% was determined1980Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
Potential antitumor agents. 33. Quantitative structure--activity relationships for mutagenic activity and antitumor activity of substituted 4'-(9-acridinylamino)methanesulfonanilide derivatives.
AID365813Cytotoxicity against human Jurkat cells by resazurin reduction test2008Bioorganic & medicinal chemistry, Aug-15, Volume: 16, Issue:16
Design, synthesis and preliminary biological evaluation of acridine compounds as potential agents for a combined targeted chemo-radionuclide therapy approach to melanoma.
AID1655304Growth inhibition of human MSTO-211H cells incubated for 72 hrs by trypan blue assay2020ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5
Synthesis, Antiproliferative Effect, and Topoisomerase II Inhibitory Activity of 3-Methyl-2-phenyl-1
AID99259Median survival time per control mice with leukemia P388 at 40 mg/kg dose injected intraperitoneally1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
Synthesis and antitumor activity of fused tetracyclic quinoline derivatives. 1.
AID365819Cytotoxicity against human fibroblast cells by Hoechst test2008Bioorganic & medicinal chemistry, Aug-15, Volume: 16, Issue:16
Design, synthesis and preliminary biological evaluation of acridine compounds as potential agents for a combined targeted chemo-radionuclide therapy approach to melanoma.
AID25311Acid dissociation constant was determined1983Journal of medicinal chemistry, Nov, Volume: 26, Issue:11
Potential antitumor agents. 39. Anilino ring geometry of amsacrine and derivatives: relationship to DNA binding and antitumor activity.
AID53621The compound was tested for the cytotoxicity against human leukemic DC-3F/ADII cell lines, activity is expressed as IC50 values.1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
9-substituted acridine derivatives with long half-life and potent antitumor activity: synthesis and structure-activity relationships.
AID1294871Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay2016European journal of medicinal chemistry, Jun-30, Volume: 116Synthesis and antiproliferative activity of 9-benzylamino-6-chloro-2-methoxy-acridine derivatives as potent DNA-binding ligands and topoisomerase II inhibitors.
AID46155In vitro evaluation for intercalating potency by using calf thymus DNA in ethidium bromide displacement assay1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
Synthesis and antitumor activity of 4-aminomethylthioxanthenone and 5-aminomethylbenzothiopyranoindazole derivatives.
AID98700Growth inhibition against cultured murine L1210 leukemia cells1983Journal of medicinal chemistry, Nov, Volume: 26, Issue:11
Potential antitumor agents. 38. 3-substituted 5-carboxamido derivatives of amsacrine.
AID316496Stability of F21T DNA quadruplex sequence d[G3(T2AG3)3] assessed as thermal denaturation by FRET analysis2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Antitumor polycyclic acridines. 20. Search for DNA quadruplex binding selectivity in a series of 8,13-dimethylquino[4,3,2-kl]acridinium salts: telomere-targeted agents.
AID396408Antiproliferative activity against human M21 cells after 48 hrs by SRB assay2008European journal of medicinal chemistry, Nov, Volume: 43, Issue:11
Novel imidazo[1,2-a]naphthyridinic systems (part 1): synthesis, antiproliferative and DNA-intercalating activities.
AID9989Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line1998Bioorganic & medicinal chemistry letters, Jan-20, Volume: 8, Issue:2
Synthesis, DNA-damaging and cytotoxic properties of novel topoisomerase II-directed bisantrene analogues.
AID98699Reduce in the cell count when drug added to the murine L1210 leukemia cell cultures for 70 h1983Journal of medicinal chemistry, Nov, Volume: 26, Issue:11
Potential antitumor agents. 39. Anilino ring geometry of amsacrine and derivatives: relationship to DNA binding and antitumor activity.
AID606655Anticancer activity against human NCI60 cells2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Discovery of 4-anilinofuro[2,3-b]quinoline derivatives as selective and orally active compounds against non-small-cell lung cancers.
AID776102Inhibition of human topoisomerase 1-mediated unwinding of pHOT1 plasmid DNA after 30 mins by agarose gel electrophoresis2013European journal of medicinal chemistry, Nov, Volume: 69Novel N-4-piperazinyl-ciprofloxacin-chalcone hybrids: synthesis, physicochemical properties, anticancer and topoisomerase I and II inhibitory activity.
AID99255Median survival time per control mice with leukemia P388 at 20 mg/kg dose injected intraperitoneally1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
Synthesis and antitumor activity of fused tetracyclic quinoline derivatives. 1.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1609096Selectivity index, ratio of CC50 for mouse RAW264.7 cells to ratio of IC50 for human T47D cells2019European journal of medicinal chemistry, Nov-15, Volume: 182Novel 4-quinoline-thiosemicarbazone derivatives: Synthesis, antiproliferative activity, in vitro and in silico biomacromolecule interaction studies and topoisomerase inhibition.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID8681Inhibitory activity against A549 cell line using MTT assay(Wild type p53)2000Journal of medicinal chemistry, Apr-20, Volume: 43, Issue:8
Antitumor polycyclic acridines. 7. Synthesis and biological properties of DNA affinic tetra- and pentacyclic acridines.
AID23103The compound was evaluated for its acid dissociation constant1987Journal of medicinal chemistry, Sep, Volume: 30, Issue:9
Potential antitumor agents. 52. Carbamate analogues of amsacrine with in vivo activity against multidrug-resistant P388 leukemia.
AID147017Ability to block cleavage of CC/CGGG site in NciI enzyme with the test compound/DNA ratio 1:8(no. of sites=10); - = no activation1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Properties of the nucleic acid photoaffinity labeling agent 3-azidoamsacrine.
AID82834Cell cytotoxicity was determined against human promyelocytic leukemia (HL60) cell line1998Bioorganic & medicinal chemistry letters, Jan-20, Volume: 8, Issue:2
Synthesis, DNA-damaging and cytotoxic properties of novel topoisomerase II-directed bisantrene analogues.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID68776Inhibitory activity against F460pv8/eto cell line using MTT assay2000Journal of medicinal chemistry, Apr-20, Volume: 43, Issue:8
Antitumor polycyclic acridines. 7. Synthesis and biological properties of DNA affinic tetra- and pentacyclic acridines.
AID1695165Inhibition of human topoisomerase 2alpha using supercoiled pNO1 plasmid DNA as substrate incubated for 30 mins by fluorescence based microplate reader analysis
AID1148372Dissociation constant, basic pKa of the compound by UV spectrophotometry1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Potential antitumor agents. 26. Anionic congeners of the 9-anilinoacridines.
AID351114Inhibition of human DNA topoisomerase 2-mediated Crithidia fasciculata kDNA decatenation using ethidium bromide staining by agarose gel electrophoresis2009Bioorganic & medicinal chemistry, May-01, Volume: 17, Issue:9
Synthesis, cytotoxic activity, DNA topoisomerase-II inhibition, molecular modeling and structure-activity relationship of 9-anilinothiazolo[5,4-b]quinoline derivatives.
AID208685Inhibitory activity against T47D cell line using MTT assay (ER+,mutant p53)2000Journal of medicinal chemistry, Apr-20, Volume: 43, Issue:8
Antitumor polycyclic acridines. 7. Synthesis and biological properties of DNA affinic tetra- and pentacyclic acridines.
AID1328421Inhibition of DltB in ltaS-deficient Staphylococcus aureus SEJ1 at 5 ug/ml after 16 to 18 hrs2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Accelerating the discovery of antibacterial compounds using pathway-directed whole cell screening.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID355288DNA damaging activity against RAD52 DNA repair gene/topoisomerase 1 deficient Saccharomyces cerevisiae GAL4:RAD52 mutant assessed as drug level required to produce 12 mm zone of inhibition assessed per 100 uL in glucose medium after 48 hrs1997Journal of natural products, Oct, Volume: 60, Issue:10
Three new pseudodistomins, piperidine alkaloids from the ascidian Pseudodistoma megalarva.
AID678716Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID54456Binding constant to poly (dA-dT) was determined in calf thymus DNA by a fluorometric method1983Journal of medicinal chemistry, Nov, Volume: 26, Issue:11
Potential antitumor agents. 39. Anilino ring geometry of amsacrine and derivatives: relationship to DNA binding and antitumor activity.
AID91916Inhibitory concentration against Human Jurkat leukemia (JLC) cell proliferation1997Journal of medicinal chemistry, Jun-20, Volume: 40, Issue:13
Synthesis and antitumor properties of N-[2-(dimethylamino)ethyl]carboxamide derivatives of fused tetracyclic quinolines and quinoxalines: a new class of putative topoisomerase inhibitors.
AID396409Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay2008European journal of medicinal chemistry, Nov, Volume: 43, Issue:11
Novel imidazo[1,2-a]naphthyridinic systems (part 1): synthesis, antiproliferative and DNA-intercalating activities.
AID1149743Half life in mouse L1210 cells allografted C3H/DBA2 F1 hybrid hybrid mouse1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Potential antitumor agents. 23. 4'-(9-Acridinylamino)alkanesulfonanilide congeners bearing hydrophilic functionality.
AID98133In vitro for cytotoxicity against murine leukemia cells (L1210)1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Potential antitumor agents. 47. 3'-Methylamino analogues of amsacrine with in vivo solid tumor activity.
AID53603The compound was tested for the cytotoxicity DC-3F cell lines1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
9-substituted acridine derivatives with long half-life and potent antitumor activity: synthesis and structure-activity relationships.
AID134223LD10 in mice1981Journal of medicinal chemistry, May, Volume: 24, Issue:5
Potential antitumor agents. 35. Quantitative relationships between antitumor (L1210) potency and DNA binding for 4'-(9-acridinylamino)methanesulfon-m-anisidide analogues.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID665987Antiproliferative activity against human COLO205 cells after 72 hrs by MTT assay2012Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11
Synthesis and cytotoxic activity of new acridine-thiazolidine derivatives.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID101091In vitro concentration required to inhibit the growth of L1210 cells in culture by 50% following a 48 hr exposure.1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Potential antitumor agents. 41. Analogues of amsacrine with electron-donor substituents in the anilino ring.
AID55124Binding constant for DNA by ethidium bromide displacement1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Potential antitumor agents. 41. Analogues of amsacrine with electron-donor substituents in the anilino ring.
AID383235Cell cycle arrest in human OVCAR-3 cells assessed as accumulation at G2/M phase at 16 uM by flow cytometry2008European journal of medicinal chemistry, Feb, Volume: 43, Issue:2
Discovery of a new anilino-3H-pyrrolo[3,2-f]quinoline derivative as potential anti-cancer agent.
AID202679Inhibitory activity against SKBR-3 cell line using MTT assay (ER-amplified erB2,mutant p53)2000Journal of medicinal chemistry, Apr-20, Volume: 43, Issue:8
Antitumor polycyclic acridines. 7. Synthesis and biological properties of DNA affinic tetra- and pentacyclic acridines.
AID1328415Inhibition of DltB S175T mutant in Staphylococcus aureus Newman up to 32 ug/ml after 16 to 18 hrs by spectrophotometric analysis2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Accelerating the discovery of antibacterial compounds using pathway-directed whole cell screening.
AID386623Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
AID678712Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID29364pKa values were determined spectrophotometrically in 20% DMF.1987Journal of medicinal chemistry, Apr, Volume: 30, Issue:4
Potential antitumor agents. 48. 3'-Dimethylamino derivatives of amsacrine: redox chemistry and in vivo solid tumor activity.
AID1544062Binding affinity to Escherichia coli pBS(SK+) DNA assessed as TOP1-mediated unwinding effect at 50 to 200 uM measured after 15 mins by EtBr staining based agarose gel electrophoresis method2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Discovery and Mechanistic Study of Tailor-Made Quinoline Derivatives as Topoisomerase 1 Poison with Potent Anticancer Activity.
AID78828In vitro for the inhibition of human colon tumor (HCT-8) cells.1987Journal of medicinal chemistry, Apr, Volume: 30, Issue:4
Potential antitumor agents. 48. 3'-Dimethylamino derivatives of amsacrine: redox chemistry and in vivo solid tumor activity.
AID657774Cytocidal activity against human MCF7 cells assessed as growth inhibition after 48 hrs by SRB assay2012European journal of medicinal chemistry, Jun, Volume: 52Imidazonaphthyridine systems (part 2): Functionalization of the phenyl ring linked to the pyridine pharmacophore and its replacement by a pyridinone ring produces intriguing differences in cytocidal activity.
AID1328418Inhibition of DltB A355E mutant in Staphylococcus aureus Newman up to 32 ug/ml after 16 to 18 hrs by spectrophotometric analysis2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Accelerating the discovery of antibacterial compounds using pathway-directed whole cell screening.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1328416Inhibition of DltB A219D mutant in Staphylococcus aureus Newman up to 32 ug/ml after 16 to 18 hrs by spectrophotometric analysis2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Accelerating the discovery of antibacterial compounds using pathway-directed whole cell screening.
AID1500670Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay2017European journal of medicinal chemistry, Sep-29, Volume: 138Design, synthesis and biological evaluation of 4-amidobenzimidazole acridine derivatives as dual PARP and Topo inhibitors for cancer therapy.
AID201364Mutagenic efficiency, measured as the concentration providing 50% inhibition of Salmonella Typhimurium strain TA 1537 growth in drug induced-mutant colonies1980Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
Potential antitumor agents. 33. Quantitative structure--activity relationships for mutagenic activity and antitumor activity of substituted 4'-(9-acridinylamino)methanesulfonanilide derivatives.
AID1133944Toxicity in ip dosed mouse assessed as optimum dose that providing maximum increase in life span administered qd for 1 to 5 days1977Journal of medicinal chemistry, Apr, Volume: 20, Issue:4
Potential antitumor agents. 22. Latentiated congeners of the 4'-(9-acridinylamino)methanesulfonanilides.
AID211292Tested for inhibition of topoisomerase II isolated from HeLa cells by DNA-cleavage assay1993Journal of medicinal chemistry, Sep-17, Volume: 36, Issue:19
Mammalian topoisomerase II inhibitory activity of 1-cyclopropyl-6,8- difluoro-1,4-dihydro-7-(2,6-dimethyl-4-pyridinyl)-4-oxo-3-quinolinecarb oxylic acid and related derivatives.
AID104131Inhibitory activity against MDA-231 cell line using MTT assay (ER-,EGFR+,mutant p53)2000Journal of medicinal chemistry, Apr-20, Volume: 43, Issue:8
Antitumor polycyclic acridines. 7. Synthesis and biological properties of DNA affinic tetra- and pentacyclic acridines.
AID95456Concentration required to reduce the growth of human Jurkat cells to 50% of control cultures1997Journal of medicinal chemistry, Aug-01, Volume: 40, Issue:16
Structure-activity relationships for the antileishmanial and antitrypanosomal activities of 1'-substituted 9-anilinoacridines.
AID78419Inhibitory activity against H460pv8 cell line using MTT assay2000Journal of medicinal chemistry, Apr-20, Volume: 43, Issue:8
Antitumor polycyclic acridines. 7. Synthesis and biological properties of DNA affinic tetra- and pentacyclic acridines.
AID1294872Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay2016European journal of medicinal chemistry, Jun-30, Volume: 116Synthesis and antiproliferative activity of 9-benzylamino-6-chloro-2-methoxy-acridine derivatives as potent DNA-binding ligands and topoisomerase II inhibitors.
AID307098Cytotoxicity against human HCT116 cells by XTT assay2007Bioorganic & medicinal chemistry letters, May-15, Volume: 17, Issue:10
Analogs of the marine alkaloid makaluvamines: synthesis, topoisomerase II inhibition, and anticancer activity.
AID100108Inhibitory activity against Lewis lung carcinoma cells2001Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12
Synthesis and cytotoxic activity of 7-oxo-7H-dibenz[f,ij]isoquinoline and 7-oxo-7H-benzo[e]perimidine derivatives.
AID355289DNA damaging activity against RAD52 DNA repair gene/topoisomerase 1 deficient Saccharomyces cerevisiae GAL4:RAD52 mutant assessed as drug level required to produce 12 mm zone of inhibition assessed per 100 uL in galactose medium after 48 hrs1997Journal of natural products, Oct, Volume: 60, Issue:10
Three new pseudodistomins, piperidine alkaloids from the ascidian Pseudodistoma megalarva.
AID150673Inhibitory concentration required to reduce murine p388 leukemia cell number to 50% of control cultures1997Journal of medicinal chemistry, Jun-06, Volume: 40, Issue:12
Structure-activity relationships for acridine-substituted analogues of the mixed topoisomerase I/II inhibitor N-[2-(dimethylamino)ethyl]acridine-4-carboxamide.
AID1328423Inhibition of DltB tn::1050 mutant in Staphylococcus aureus USA300 JE2 at 5 ug/ml after 16 to 18 hrs2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Accelerating the discovery of antibacterial compounds using pathway-directed whole cell screening.
AID211122Effect of dose dependent inhibition of TOPO II-catalyzed kDNA decatenation in vitro1994Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22
Inhibition of topoisomerase II catalytic activity by pyridoacridine alkaloids from a Cystodytes sp. ascidian: a mechanism for the apparent intercalator-induced inhibition of topoisomerase II.
AID135602Molar dose providing 40 percent increase in the life span of leukemic mice1981Journal of medicinal chemistry, May, Volume: 24, Issue:5
Potential antitumor agents. 35. Quantitative relationships between antitumor (L1210) potency and DNA binding for 4'-(9-acridinylamino)methanesulfon-m-anisidide analogues.
AID1337598Displacement of ethidium bromide from calf thymus DNA measured after 30 mins by fluorescence quenching assay2017European journal of medicinal chemistry, Jan-05, Volume: 125Fluorescein hydrazones: A series of novel non-intercalative topoisomerase IIα catalytic inhibitors induce G1 arrest and apoptosis in breast and colon cancer cells.
AID355579Antiproliferative activity against human HT-29 cells at 10 ug after 48 hrs by two-layer agar-diffusion method
AID1404843Inhibition of human topoisomerase 2 assessed as cleavage complex formation at 10 uM using pBS-SK(+) DNA as substrate after 60 mins by agarose gel electrophoresis2018European journal of medicinal chemistry, Jul-15, Volume: 155Design, synthesis, molecular modeling and anti-proliferative evaluation of novel quinoxaline derivatives as potential DNA intercalators and topoisomerase II inhibitors.
AID347896Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Synthesis and antitumor activity of novel amsacrine analogs: the critical role of the acridine moiety in determining their biological activity.
AID111220In vitro anticancer activity against B6D2F-1 mice bearing P388 leukemia measured by the average weight change(g) after day 9 at an intravenous dose of 8(mg/kg).1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Synthesis and structure-activity relationships of potential anticancer agents: alkylcarbamates of 3-(9-acridinylamino)-5-hydroxymethylaniline.
AID111216In vitro anticancer activity against B6D2F-1 mice bearing P388 leukemia measured by the average weight change(g) after day 9 at an intravenous dose of 12(mg/kg).1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Synthesis and structure-activity relationships of potential anticancer agents: alkylcarbamates of 3-(9-acridinylamino)-5-hydroxymethylaniline.
AID110718In vitro anticancer activity against B6D2F-1 mice bearing P388 leukemia measured by the Average survival time(day+/-SD) at an intravenous dose of 18(mg/kg).1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Synthesis and structure-activity relationships of potential anticancer agents: alkylcarbamates of 3-(9-acridinylamino)-5-hydroxymethylaniline.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1148474Antitumor activity against mouse L1210 cells allografted in ip dosed BDF1 mouse at optimum dose administered qd for 5 days relative to control1978Journal of medicinal chemistry, Jul, Volume: 21, Issue:7
Potenial antitumor agents. 28. Deoxyribonucleic acid polyintercalating agents.
AID678722Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID55643Binding constant to poly[d(AT)] by ethidium bromide displacement1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Potential antitumor agents. 59. Structure-activity relationships for 2-phenylbenzimidazole-4-carboxamides, a new class of "minimal" DNA-intercalating agents which may not act via topoisomerase II.
AID1148477Lipophilic-hydrophilic balance, Rm of the compound by reversed-phase chromatographic analysis1978Journal of medicinal chemistry, Jul, Volume: 21, Issue:7
Potenial antitumor agents. 28. Deoxyribonucleic acid polyintercalating agents.
AID1695166Cytotoxicity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
AID99252Median survival time per control mice with leukemia P388 at 10 mg/kg dose injected intraperitoneally1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
Synthesis and antitumor activity of fused tetracyclic quinoline derivatives. 1.
AID665988Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay2012Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11
Synthesis and cytotoxic activity of new acridine-thiazolidine derivatives.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID25559Ionization constant (pKa)1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Potential antitumor agents. 36. Quantitative relationships between experimental antitumor activity, toxicity, and structure for the general class of 9-anilinoacridine antitumor agents.
AID26756DNA binding dissociation constant as KD1984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
Interactions of antitumor drugs with natural DNA: 1H NMR study of binding mode and kinetics.
AID225938Log K value for DNA binding to poly[d(G-C)]1983Journal of medicinal chemistry, Nov, Volume: 26, Issue:11
Potential antitumor agents. 38. 3-substituted 5-carboxamido derivatives of amsacrine.
AID120026Average tumor volume of the E0771 mammary adenocarcinoma,1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
9-substituted acridine derivatives with long half-life and potent antitumor activity: synthesis and structure-activity relationships.
AID134904The long term cures (LTC) value is the number of mice in a group with no palpable tumor.1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
Synthesis and antitumor activity of 4-aminomethylthioxanthenone and 5-aminomethylbenzothiopyranoindazole derivatives.
AID150664Inhibitory activity against Murine p38 leukemia1999Journal of medicinal chemistry, Jul-01, Volume: 42, Issue:13
Structure-activity relationships for substituted bis(acridine-4-carboxamides): a new class of anticancer agents.
AID103235Inhibitory activity against MCF-7/adr cell line using MTT assay2000Journal of medicinal chemistry, Apr-20, Volume: 43, Issue:8
Antitumor polycyclic acridines. 7. Synthesis and biological properties of DNA affinic tetra- and pentacyclic acridines.
AID211311Percent of DNA remaining uncut after incubation with Topoisomerase II at 1 uM concentration1998Bioorganic & medicinal chemistry letters, Jan-20, Volume: 8, Issue:2
Synthesis, DNA-damaging and cytotoxic properties of novel topoisomerase II-directed bisantrene analogues.
AID152987Ratio of IC50 value of P388/A and P388/W cell lines1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Potential antitumor agents. 59. Structure-activity relationships for 2-phenylbenzimidazole-4-carboxamides, a new class of "minimal" DNA-intercalating agents which may not act via topoisomerase II.
AID107808Viability of L5178Y cells was evaluated at dose 0.005 mg/mL in light condition (expt-II)1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Properties of the nucleic acid photoaffinity labeling agent 3-azidoamsacrine.
AID107807Viability of L5178Y cells was evaluated at dose 0.005 mg/mL in dark condition (expt-II)1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Properties of the nucleic acid photoaffinity labeling agent 3-azidoamsacrine.
AID1148375Antitumor activity against mouse L1210 cells transfected in C3H/DBA2 F1 mouse assessed as increase in life span at optimum dose administered ip qd for 5 days relative to control1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Potential antitumor agents. 26. Anionic congeners of the 9-anilinoacridines.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,229)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990518 (42.15)18.7374
1990's429 (34.91)18.2507
2000's151 (12.29)29.6817
2010's100 (8.14)24.3611
2020's31 (2.52)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 39.98

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index39.98 (24.57)
Research Supply Index7.26 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index63.50 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (39.98)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials127 (9.82%)5.53%
Reviews64 (4.95%)6.00%
Case Studies43 (3.33%)4.05%
Observational0 (0.00%)0.25%
Other1,059 (81.90%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (9)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Phase-I/II Trial to Assess the Safety and Efficacy of Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML (FLAMSACla [NCT05807932]Phase 1/Phase 238 participants (Anticipated)Interventional2023-06-26Recruiting
A Randomized Phase III Study of Intensive Consolidation With High Dose Cytosine Arabinoside in Acute Myelogenous Leukemia (AML-8B) [NCT01324063]Phase 3160 participants (Anticipated)Interventional1986-11-30Completed
A PHASE I-II MULTICENTER STUDY OF THE CLORETAZINE-DAUNORUBICIN-ARACYTINE COMBINATION FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) WITH UNFAVORABLE CYTOGENETICS [NCT00840684]Phase 1/Phase 2135 participants (Anticipated)Interventional2009-01-31Completed
AML2003 - Randomized Comparison Between Standard-Therapy and Intensified Therapy for Adult Acute Myeloid Leukemia Patients <= 60 Years. A Prospective, Randomized, Multi-center Therapy-Optimizing-Study. [NCT00180102]Phase 4600 participants (Anticipated)Interventional2003-12-31Completed
Dexamethasone Plus Salvage Chemotherapy Versus Salvage Chemotherapy Alone in Patients With First Relapsed or Refractory Acute Myeloid Leukemia: a Randomized, Controlled, Open-label, Multicenter, Phase III Study [NCT03765541]Phase 3142 participants (Anticipated)Interventional2020-01-13Recruiting
ACUTE MYELOID LEUKAEMIA TRIAL 12 [NCT00002658]Phase 32,000 participants (Anticipated)Interventional1994-01-31Active, not recruiting
Medical Research Council Working Party on Leukaemia in Childhood Acute Myeloid Leukaemia Trial 12 [NCT00003436]Phase 32,000 participants (Anticipated)Interventional1998-07-31Completed
RANDOMIZED PHASE III STUDY TO EVALUATE THE VALUE OF rHuG-CSF IN INDUCTION AND OF AN ORAL SCHEDULE AS CONSOLIDATION TREATMENT IN ELDERLY PATIENTS WITH ACUTE MYELOGENOUS LEUMEKIA (AML-13 PROTOCOL) [NCT00002719]Phase 3500 participants (Anticipated)Interventional1995-12-31Completed
A Randomized Multi-Center Treatment Study (COALL 08-09) to Improve the Survival of Children With Acute Lymphoblastic Leukemia on Behalf of the German Society of Pediatric Hematology and Oncology [NCT01228331]Phase 2/Phase 3745 participants (Actual)Interventional2010-10-31Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]